

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/123673 A1

(51) International Patent Classification⁷: C07D 209/42, 401/04, A61K 31/404, A61P 29/00

(74) Agent: MCNEENEY, Stephen, Phillip; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(21) International Application Number:

PCT/GB2005/002391

(22) International Filing Date: 17 June 2005 (17.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/580,401 18 June 2004 (18.06.2004) US

(71) Applicant (for all designated States except US): BI-OLIPOX AB [SE/SE]; P.O. Box 6280, S-102 34 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): OLOFSSON, Kristofer [SE/SE]; Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE). SUNA, Edgars [LV/LV]; Latvian Institute of Organic Synthesis, 21 Aizkraukles Str., LV-1006 Riga (LV). PELCMAN, Benjamin [SE/SE]; Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE). OZOLA, Vita [LV/LV]; Latvian Institute of Organic Synthesis, 21 Aizkraukles Str., LV-1006 Riga (LV). KATKEVICS, Martins [LV/LV]; Latvian Institute of Organic Synthesis, 21 Aizkraukles Str., LV-1006 Riga (LV). KALVINS, Ivars [LV/LV]; Latvian Institute of Organic Synthesis, 21 Aizkraukles Str., LV-1006 Riga (LV).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION



(57) Abstract: There is provided a compound of formula: (I), wherein X, R¹, R², R³, R⁴, R⁵ and R⁶ have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.

WO 2005/123673 A1

BEST AVAILABLE COPY



INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

Field of the Invention

5 This invention relates to novel pharmaceutically-useful compounds, which compounds are useful as inhibitors of enzymes belonging to the membrane-associated proteins in the eicosanoid and glutathione metabolism (MAPEG) family. Members of the MAPEG family include the microsomal prostaglandin E synthase-1 (mPGES-1), 5-lipoxygenase-activating protein (FLAP), leukotriene C₄ synthase and microsomal glutathione S-transferases (MGST1, MGST2 and MGST3). The compounds are of potential utility in 10 the treatment of inflammatory diseases including respiratory diseases. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to synthetic routes for 15 their production

Background of the Invention

There are many diseases/disorders that are inflammatory in their nature. 20 One of the major problems associated with existing treatments of inflammatory conditions is a lack of efficacy and/or the prevalence of side effects (real or perceived).

Inflammatory diseases that affect the population include asthma, 25 inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, rhinitis, conjunctivitis and dermatitis.

Inflammation is also a common cause of pain. Inflammatory pain may arise for numerous reasons, such as infection, surgery or other trauma. 30 Moreover, several diseases including malignancies and cardiovascular

diseases are known to have inflammatory components adding to the symptomatology of the patients.

Asthma is a disease of the airways that contains elements of both 5 inflammation and bronchoconstriction. Treatment regimens for asthma are based on the severity of the condition. Mild cases are either untreated or are only treated with inhaled β -agonists which affect the bronchoconstriction element, whereas patients with more severe asthma typically are treated regularly with inhaled corticosteroids which to a large extent are anti-10 inflammatory in their nature.

Another common disease of the airways with inflammatory and bronchoconstrictive components is chronic obstructive pulmonary disease (COPD). The disease is potentially lethal, and the morbidity and mortality 15 from the condition is considerable. At present, there is no known pharmacological treatment capable of changing the course of the disease.

The cyclooxygenase (COX) enzyme exists in two forms, one that is constitutively expressed in many cells and tissues (COX-1), and one that is 20 induced by pro-inflammatory stimuli, such as cytokines, during an inflammatory response (COX-2).

COXs metabolise arachidonic acid to the unstable intermediate prostaglandin H₂ (PGH₂). PGH₂ is further metabolised to other 25 prostaglandins including PGE₂, PGF_{2a}, PGD₂, prostacyclin and thromboxane A₂. These arachidonic acid metabolites are known to have pronounced physiological and pathophysiological activity including pro-inflammatory effects.

PGE₂ in particular is known to be a strong pro-inflammatory mediator, and is also known to induce fever and pain. Consequently, numerous drugs have been developed with a view to inhibiting the formation of PGE₂, including "NSAIDs" (non-steroidal antiinflammatory drugs) and "coxibs" (selective COX-2 inhibitors). These drugs act predominantly by inhibition of COX-1 and/or COX-2, thereby reducing the formation of PGE₂.

However, the inhibition of COXs has the disadvantage that it results in the reduction of the formation of all metabolites of arachidonic acid, some of which are known to have beneficial properties. In view of this, drugs which act by inhibition of COXs are therefore known/suspected to cause adverse biological effects. For example, the non-selective inhibition of COXs by NSAIDs may give rise to gastrointestinal side-effects and affect platelet and renal function. Even the selective inhibition of COX-2 by coxibs, whilst reducing such gastrointestinal side-effects, is believed to give rise to cardiovascular problems.

An alternative treatment of inflammatory diseases that does not give rise to the above-mentioned side effects would thus be of real benefit in the clinic. In particular, a drug that inhibits (preferably selectively) the transformation of PGH₂ to the pro-inflammatory mediator PGE₂ might be expected to reduce the inflammatory response in the absence of a corresponding reduction of the formation of other, beneficial arachidonic acid metabolites. Such inhibition would accordingly be expected to alleviate the undesirable side-effects mentioned above.

PGH₂ may be transformed to PGE₂ by prostaglandin E synthases (PGES). Two microsomal prostaglandin E synthases (mPGES-1 and mPGES-2), and one cytosolic prostaglandin E synthase (cPGES) have been described.

The leukotrienes (LTs) are formed from arachidonic acid by a set of enzymes distinct from those in the COX / PGES pathway. Leukotriene B₄ is known to be a strong proinflammatory mediator, while the cysteinyl-containing leukotrienes C₄, D₄ and E₄ (CysLTs) are mainly very potent 5 bronchoconstrictors and have thus been implicated in the pathobiology of asthma. The biological activities of the CysLTs are mediated through two receptors designated CysLT₁ and CysLT₂. As an alternative to steroids, leukotriene receptor antagonists (LTRas) have been developed in the treatment of asthma. These drugs may be given orally, but do not control 10 inflammation satisfactorily. The presently used LTRas are highly selective for CysLT₁. It may be hypothesised that better control of asthma, and possibly also COPD, may be attained if the activity of both of the CysLT receptors could be reduced. This may be achieved by developing unselective LTRas, but also by inhibiting the activity of proteins, e.g. 15 enzymes, involved in the synthesis of the CysLTs. Among these proteins, 5-lipoxygenase, 5-lipoxygenase-activating protein (FLAP), and leukotriene C₄ synthase may be mentioned. A FLAP inhibitor would also decrease the formation of the proinflammatory LTB₄.

20 mPGES-1, FLAP and leukotriene C₄ synthase belong to the membrane-associated proteins in the eicosanoid and glutathione metabolism (MAPEG) family. Other members of this family include the microsomal glutathione S-transferases (MGST1, MGST2 and MGST3). For a review, c.f. P.-J. Jacobsson *et al* in *Am. J. Respir. Crit. Care Med.* **161**, S20 (2000). It is well 25 known that compounds prepared as antagonists to one of the MAPEGs may also exhibit inhibitory activity towards other family members, c.f. J. H Hutchinson *et al* in *J. Med. Chem.* **38**, 4538 (1995) and D. Claveau *et al* in *J. Immunol.* **170**, 4738 (2003). The former paper also describes that such compounds may also display notable cross-reactivity with proteins in the

arachidonic acid cascade that do not belong to the MAPEG family, e.g. 5-lipoxygenase.

Thus, agents that are capable of inhibiting the action of mPGES-1, and thus
5 reducing the formation of the specific arachidonic acid metabolite PGE₂, are likely to be of benefit in the treatment of inflammation. Further, agents that are capable of inhibiting the action of the proteins involved in the synthesis of the leukotrienes are also likely to be of benefit in the treatment of asthma and COPD.

10

Prior Art

Certain specific 1(N)-phenylindole-2-carboxylate derivatives have been disclosed by Rajur *et al* in *Ind. J. Chem Section B: Organic Chemistry Including Medicinal Chemistry*, 31B, 551 (1992) as chemical intermediates useful in the synthesis of antiallergic agents. The use of these intermediates in the treatment of inflammatory disorders is not suggested in this document.

20 Various indole-2-carboxylates, and derivatives thereof, have been disclosed in international patent applications WO 01/30343, WO 96/03377, WO 01/00197 and WO 99/33800, US patents Nos. 5,189,054 and 4,960,786, European patent application EP 483 881 and Italian Patent No. 1303260. However, none of these documents disclose or suggest the use of the indole-25 2-carboxylates in the treatment of inflammation.

Similar indole-2-carboxylates have been disclosed for potential use in the treatment of inflammation in international patent applications WO 99/07678, WO 99/07351, WO 00/46198, WO 00/46197, WO 00/46195, 30 WO 00/46199, WO 96/18393, WO 02/30895, WO 99/05104, WO 01/32621

and WO 2005/005415, US patents Nos. 5,081,145 and 5,081,138 and European patent applications EP 166 591 and EP 985 666. However, none of these documents disclose such compounds in which an aromatic group is directly attached to the ring system *via* the indole nitrogen.

5


International patent application WO 94/13662 and European patent application EP 186 367 also mention indoles for potential use in the treatment of inflammation. However, these documents do not mention or suggest compounds in which the benzenoid moiety of the indole is 10 substituted with an aromatic ring.

International patent applications WO 94/14434, WO 99/43672, WO 98/08818, WO 99/43654 and WO 99/43651 and US patents Nos. 6,500,853 15 and 6,630,496 also describe structurally similar indoles for such potential use. However, there is no specific disclosure in any of these documents of indole-2-carboxylates in which an aromatic group is directly attached *via* the indole nitrogen.

Disclosure of the Invention

20

According to the invention there is provided a compound of formula I,



25 wherein

X represents H or a halo group;

R¹ represents an aryl group or a heteroaryl group, both of which groups are optionally substituted by one or more substituents selected from A;

5

one of the groups R², R³, R⁴ and R⁵ represents an aryl group or a heteroaryl group (both of which are optionally substituted by one or more substituents selected from A) and:

10 a) the other groups are independently selected from hydrogen, G¹, an aryl group, a heteroaryl group (which latter two groups are optionally substituted by one or more substituents selected from A), C₁₋₈ alkyl and a heterocycloalkyl group (which latter two groups are optionally substituted by one or more substituents selected from G¹ and/or Z¹); and/or

15 b) any two other groups which are adjacent to each other are optionally linked to form, along with two atoms of the essential benzene ring in the compound of formula I, a 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁶, -OR⁶ and =O;

20

A represents, on each occasion when mentioned above:

I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B;

25 II) C₁₋₈ alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G¹ and/or Z¹;

III) a G¹ group; or

IV) two A substituents may be linked together to form, along with at least two (e.g. adjacent) atoms of the aryl or heteroaryl group to which the two A substituents are attached, a further 3- to 5-membered ring, which ring 30 optionally contains 1 to 3 (e.g. 1 or 2) heteroatoms and/or 1 to 2 (e.g. 1)

double bonds, and which is optionally substituted by halo or C₁₋₈ alkyl, which latter group is optionally substituted by halo;

R⁶ represents, on each occasion when mentioned above:

5 I) hydrogen;
II) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B; or
III) C₁₋₈ alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G¹ and/or Z¹;

10

G¹ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹-R⁷;

wherein A¹ represents a single bond or a spacer group selected from -C(O)A²-, -S(O)_nA³-, -N(R⁸)A⁴- or -OA⁵-, in which:

15 A² and A³ independently represent a single bond, -O-, -N(R⁸)- or -C(O)-;
A⁴ and A⁵ independently represent a single bond, -C(O)-, -C(O)N(R⁸)-, -C(O)O-, -S(O)_n- or -S(O)_nN(R⁸)-;

Z¹ represents, on each occasion when mentioned above, =O, =S, =NOR⁷,
20 =NS(O)_nN(R⁸)(R⁷), =NCN or =C(H)NO₂;

B represents, on each occasion when mentioned above:

I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G², methylenedioxy, 25 difluoromethylenedioxy and/or dimethylmethylenedioxy;
II) C₁₋₈ alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G² and/or Z²;
III) a G² group; or
IV) methylenedioxy, difluoromethylenedioxy or dimethylmethylen-
30 dioxy;

G^2 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^6-R^9$;

wherein A^6 represents a single bond or a spacer group selected from

5 $-C(O)A^7$, $-S(O)_nA^8$, $-N(R^{10})A^9$ or $-OA^{10}$, in which:

A^7 and A^8 independently represent a single bond, $-O-$, $-N(R^{10})-$ or $-C(O)-$;

A^9 and A^{10} independently represent a single bond, $-C(O)-$, $-C(O)N(R^{10})-$, $-C(O)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{10})-$;

10 Z^2 represents, on each occasion when mentioned above, $=O$, $=S$, $=NOR^9$, $=NS(O)_nN(R^{10})(R^9)$, $=NCN$ or $=C(H)NO_2$;

R^7 , R^8 , R^9 and R^{10} are independently selected from:

i) hydrogen;

15 ii) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^3 , methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy;

iii) C_{1-8} alkyl or a heterocycloalkyl group, both of which are optionally substituted by G^3 and/or Z^3 ; or

20 any pair of R^7 and R^8 , or R^9 and R^{10} , may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms a further 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is optionally substituted by one or more substituents selected from G^3 and/or Z^3 ;

25

G^3 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^{11}-R^{11}$;

wherein A^{11} represents a single bond or a spacer group selected from

$-C(O)A^{12}$, $-S(O)_nA^{13}$, $-N(R^{12})A^{14}$ or $-OA^{15}$, in which:

30 A^{12} and A^{13} independently represent a single bond, $-O-$, $-N(R^{12})-$ or $-C(O)-$;

A^{14} and A^{15} independently represent a single bond, $-C(O)-$, $-C(O)N(R^{12})-$, $-C(O)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{12})-$;

Z^3 represents, on each occasion when mentioned above, $=O$, $=S$, $=NOR^{11}$,
5 $=NS(O)_nN(R^{12})(R^{11})$, $=NCN$ or $=C(H)NO_2$;

n represents, on each occasion when mentioned above, 1 or 2;

R^{11} and R^{12} are independently selected from:

10 i) hydrogen;
ii) C_{1-6} alkyl or a heterocycloalkyl group, both of which groups are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl, $-N(R^{13})(R^{14})$, $-O(R^{13})$ and $=O$; and

15 iii) an aryl or heteroaryl group, both of which are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl, $-N(R^{13})(R^{14})$ and $-O(R^{13})$; or

20 any pair R^{11} and R^{12} may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms a further 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl, $-N(R^{13})(R^{14})$, $-O(R^{13})$ and $=O$;

25 R^{13} and R^{14} are independently selected from hydrogen and C_{1-4} alkyl, which latter group is optionally substituted by one or more halo groups;

or a pharmaceutically-acceptable salt thereof,

provided that, when R^2 , R^4 and R^5 all represent H, R^3 represents unsubstituted phenyl, R^6 represents ethyl, and X represents H or Cl, then R^1 does not represent 2,4-dinitrophenyl,

5 which compounds and salts are referred to hereinafter as "the compounds of the invention".

Pharmaceutically-acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for 10 example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. *in vacuo*, by freeze-drying or by filtration). Salts may also 15 be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

Compounds of the invention may contain double bonds and may thus exist 20 as *E* (*entgegen*) and *Z* (*zusammen*) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.

Compounds of the invention may also exhibit tautomerism. All tautomeric 25 forms and mixtures thereof are included within the scope of the invention.

Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. 30 chromatography or fractional crystallisation. The various stereoisomers

may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under 5 conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the 10 diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.

15 Unless otherwise specified, C_{1-q} alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a C_{3-q} cycloalkyl group). C_{3-q} cycloalkyl groups that may be mentioned include monocyclic or 20 bicyclic alkyl groups, which cycloalkyl groups may further be bridged. Further, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (forming, for example, a C_{3-q} cycloalkenyl, a C_8 cycloalkynyl or, more particularly, a C_{2-q} alkenyl or a 25 C_{2-q} alkynyl group). Further, in the case where the substituent is another cyclic compound, then the cyclic substituent may be attached through a single atom on the cycloalkyl group, forming a so-called "spiro"-compound.

30 The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.

Heterocycloalkyl groups that may be mentioned include those in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the 5 ring system is between three and twelve (e.g. between five and ten). Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C_{2-q} (e.g. C_{3-q}) heterocycloalkenyl (where q is the upper limit of the range) or a C_{3-q} heterocycloalkynyl group. C_{2-q} heterocycloalkyl groups that may 10 be mentioned include aziridinyl, azetidinyl, dihydropyranyl, dihydropyridyl, dihydropyrrrolyl (including 2,5-dihydropyrrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxanyl (including 1,3-dioxanyl and 1,4-dioxanyl), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), imidazolidinyl, imidazolinyl, morpholinyl, oxetanyl, oxiranyl, piperazinyl, 15 piperidinyl, pyranyl, pyrazolidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolanyl, 3-sulfolenyl, tetrahydropyranyl, tetrahydrofuranlyl, tetrahydropyridyl, thietanyl, thiiranyl, thiolanyl, thiomorpholinyl, trithianyl (including 1,3,5-trithianyl), tropanyl and the like. Other heterocycloalkyl 20 groups that may be mentioned include 7-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 6-azabicyclo-[3.2.1]octanyl, 8-azabicyclo[3.2.1]-octanyl, 7-oxabicyclo[2.2.1]heptanyl and 6-oxabicyclo[3.2.1]octanyl. Heterocycloalkyl groups that may be mentioned include monocyclic and 25 bicyclic heterocycloalkyl groups, which groups may further be bridged. Substituents on heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the other substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyl group, forming a so-called "spiro"-compound. The point of attachment of heterocycloalkyl groups may be *via* any atom in the ring system including 30 (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on

any fused carbocyclic ring that may be present as part of the ring system.

Heterocycloalkyl groups may also be in the *N*- or *S*- oxidised form.

For the avoidance of doubt, the term "bicyclic", when employed in the 5 context of cycloalkyl and heterocycloalkyl groups refers to such groups in which the second ring is formed between two adjacent atoms of the first ring. The term "bridged", when employed in the context of cycloalkyl or heterocycloalkyl groups refers to monocyclic or bicyclic groups in which two non-adjacent atoms are linked by either an alkylene or heteroalkylene 10 chain (as appropriate).

Aryl groups that may be mentioned include C₆₋₁₃ (e.g. C₆₋₁₀) aryl groups.

Such groups may be monocyclic or bicyclic and have between 6 and 13 (e.g. 10) ring carbon atoms, in which at least one ring is aromatic. C₆₋₁₃ aryl

15 groups include phenyl, naphthyl and the like, such as fluorenyl and, more particularly, 1,2,3,4-tetrahydronaphthyl, indanyl, and indenyl. The point of attachment of aryl groups may be *via* any atom of the ring system. However, when aryl groups are bicyclic or tricyclic, they are preferably linked to the rest of the molecule *via* an aromatic ring.

20

Heteroaryl groups that may be mentioned include those which have between 5 and 10 members. Such groups may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic and wherein at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a 25 heteroatom). Heterocyclic groups that may be mentioned include acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiazolyl (including 2,1,3-benzothiazolyl), benzoxadiazolyl (including 2,1,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1,4- 30 benzoxazinyl), benzoxazolyl, benzimidazolyl, benzomorpholinyl,

benzosenadiazolyl (including 2,1,3-benzosenadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1,2- α]pyridyl, indazolyl, indoliny, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiaziolyl, isoxazolyl, 5 naphthyridinyl (including 1,5-naphthyridinyl and 1,8-naphthyridinyl), oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl and 1,3,4-oxadiazolyl), oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolizinyl, quinoxalinyl, tetrahydroisoquinolinyl (including 1,2,3,4-tetrahydroisoquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl), tetrahydroquinolinyl (including 1,2,3,4-tetrahydroquinolinyl and 5,6,7,8-tetrahydroquinolinyl), tetrazolyl, thiadiazolyl (including 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl and 1,3,4-thiadiazolyl), thiazolyl, thiochromanyl, thienyl, triazolyl (including 1,2,3-triazolyl, 1,2,4-triazolyl and 1,3,4-triazolyl) and the like. Substituents on heteraryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heteraryl groups may be *via* any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. However, when heteraryl groups are bicyclic or tricyclic, they are preferably linked to the rest of the molecule *via* an aromatic ring. Heteraryl groups may also be in the *N*- or *S*- oxidised form.

25 Heteroatoms that may be mentioned include phosphorus, silicon, boron, tellurium, preferably, selenium and, more preferably oxygen, nitrogen and/or sulfur.

For the avoidance of doubt, optionally substituted methylenedioxy groups, when attached to a ring system, are formed between any two adjacent atoms of the ring system.

5 For the avoidance of doubt, in cases in which the identity of two or more substituents in a compound of the invention may be the same, the actual identities of the respective substituents are not in any way interdependent. For example, in the situation in which R¹, and any one of R² to R⁵, both represent aryl groups substituted by one or more C₁₋₈ alkyl groups, the alkyl 10 groups in question may be the same or different. Similarly, when groups are substituted by more than one substituent as defined herein, the identities of those individual substituents are not to be regarded as being interdependent. For example, when R¹ represents e.g. an aryl group substituted by G¹ in addition to, for example, C₁₋₈ alkyl, which latter group 15 is substituted by G¹, the identities of the two G¹ groups are not to be regarded as being interdependent.

Compounds of the invention that may be mentioned include those hereinbefore defined, in which, when R¹ represents phenyl substituted by 20 one or more (e.g. two) A groups and A represents G¹, then:

- G¹ represents halo, cyano, -N₃, -ONO₂ or -A¹-R⁷; and/or
- when G¹ represents -NO₂, then R⁶ represents:
 - hydrogen;
 - an aryl group or a heteroaryl group, both of which are 25 optionally substituted by one or more substituents selected from B; or
 - methyl, C₃₋₈ alkyl or a heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G¹ and/or Z¹.

Further compounds of the invention that may be mentioned include those in which:

A² and A³ independently represent a single bond, -O- or -N(R⁸)-;

Z¹ represents, on each occasion when mentioned above, =O, =NOR⁷,
5 =NS(O)_nN(R⁸)(R⁷), =NCN or =C(H)NO₂;

A⁷ and A⁸ independently represent a single bond, -O- or -N(R¹⁰)-;

Z² represents, on each occasion when mentioned above, =O, =NOR⁹,
=NS(O)_nN(R¹⁰)(R⁹), =NCN or =C(H)NO₂;

A¹² and A¹³ independently represent a single bond, -O- or -N(R¹²)-; and/or
10 Z³ represents, on each occasion when mentioned above, =O, =NOR¹¹,
=NS(O)_nN(R¹²)(R¹¹), =NCN or =C(H)NO₂.

Preferred compounds of the invention include those in which:

G¹ represents halo, cyano, -N₃, -NO₂ or -A¹-R⁷;

A⁴ and A⁵ independently represent a single bond, -C(O)-, -C(O)N(R⁸)- or
-C(O)O-;

Z¹ represents =NOR⁷, =NCN or, preferably, =O;

G² represents cyano, -N₃ or, more preferably, halo, -NO₂ or -A⁶-R⁹;

A⁶ represents -N(R¹⁰)A⁹- or -OA¹⁰-;

20 A⁹ represents -C(O)N(R¹⁰)-, -C(O)O- or, more preferably, a single bond or
-C(O)-;

A¹⁰ represents A⁹ and, preferably, a single bond;

Z² represents =NOR⁹ or =NCN or, more preferably, =O;

G³ represents halo, -NO₂ or -A¹¹-R¹¹;

25 A¹¹ represents a single bond, -C(O)A¹², -N(R¹²)A¹⁴ or -OA¹⁵;

A¹² represents a single bond or -O-;

A¹⁴ and A¹⁵ independently represent -C(O)- or, more preferably, a single
bond;

Z³ represents =O;

30 n represents 2;

when either of R¹¹ and R¹² represent optionally substituted C₁₋₆ alkyl, the optional substituent is one or more halo groups;

when either of R¹³ and R¹⁴ represent optionally substituted C₁₋₄ alkyl, the optional substituent is one or more fluoro groups.

5

Preferred compounds of the invention include those in which R¹ and (when they represent an aryl or heteroaryl group) R², R³, R⁴ and/or R⁵ represent an optionally substituted phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl (e.g. 1-imidazolyl, 2-imidazolyl or 4-imidazolyl), oxazolyl, 10 isoxazolyl, thiazolyl, pyridyl (e.g. 2-pyridyl, 3-pyridyl or 4-pyridyl), indazolyl, indolyl, indolinyl, isoindolinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinolizinyl, benzofuranyl, isobenzofuranyl, chromanyl, benzothienyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, 15 quinazolinyl, quinoxalinyl, 1,3-benzodioxolyl, benzothiazolyl, and/or benzodioxanyl, group. Other groups that may be mentioned include optionally substituted 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl and tetrazolyl. Particularly preferred values include optionally substituted quinolinyl and pyrimidinyl and, more particularly, 20 phenyl, naphthyl and pyridyl.

Optional substituents on such R¹, R², R³, R⁴ and R⁵ groups are preferably selected from:

cyano;

25 -C(O)N(R¹⁵)R¹⁶;

heterocycloalkyl, such as a nitrogen-containing 4- to 8-membered (e.g. 5- to 6-membered) heterocycloalkyl group, optionally containing one or more unsaturations and optionally substituted by one or more halo or C₁₋₃ alkyl groups;

heteroaryl, such as a 5- or 6-membered nitrogen-containing heteroaryl group, optionally substituted by one or more halo or C₁₋₃ alkyl groups; or are more preferably selected from:

-NO₂;

5 halo (e.g. fluoro, chloro or bromo);

C₁₋₆ alkyl, which alkyl group may be linear or branched (e.g. C₁₋₄ alkyl (including methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl or *t*-butyl), *n*-pentyl, isopentyl, *n*-hexyl or *iso*hexyl), cyclic (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl); part-cyclic (e.g. cyclobutylmethyl or cyclopropylmethyl), unsaturated (e.g. ethylene, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 4-pentenyl or 5-hexenyl) and/or optionally substituted with one or more groups selected from halo (e.g. fluoro, so forming fluoromethyl, difluoromethyl or trifluoromethyl), -C(O)OR¹⁵ and -OR¹⁵;

15 -OR¹⁵;

-N(R¹⁵)R¹⁶; and

-S(O)₂R¹⁵;

wherein R¹⁵ and R¹⁶ independently represent, on each occasion when mentioned above, H, a heterocycloalkyl group optionally substituted by one or more C₁₋₄ alkyl groups (such as a 4-methylpiperazinyl group) or C₁₋₆ alkyl (such as cyclopentyl, cyclopropyl or, preferably, methyl, ethyl, ethylene, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *t*-butyl or cyclobutylmethyl), which latter group is optionally substituted by one or more substituents selected from halo (e.g. fluoro) groups (so forming, for example, a fluoromethyl, difluoromethyl or trifluoromethyl group), -OR¹⁷, -N(R¹⁸)R¹⁹, -C(O)OR¹⁷ and -C(O)N(R¹⁸)R¹⁹;

wherein R¹⁷, R¹⁸ and R¹⁹ independently represent, on each occasion when mentioned above, H, C₁₋₆ alkyl (such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *t*-butyl), which alkyl groups are optionally substituted by one or more halo (especially fluoro) groups; or

R¹⁸ and R¹⁹ are linked to form a 4- to 8-membered ring optionally containing a further 1 to 2 heteroatoms (e.g. a pyrrolidinyl or a piperazinyl group), which ring is optionally substituted by a C₁₋₃ alkyl group (such as methyl).

5

Preferred values of R⁶ include C₁₋₄ alkyl and, particularly, H.

Preferred values of X include H, Cl and Br.

10 More preferred compounds include those in which:

R¹ represents an aryl group such as a phenyl or naphthyl (e.g. 2-naphthyl) group or a heteroaryl group such as a quinolinyl or, preferably, a pyridyl group, both of which are optionally substituted by one or two A groups;

R² represents G¹ or, more preferably, hydrogen;

15 R³ and R⁴ independently represent G¹ or, more preferably, hydrogen, an aryl group such as a phenyl group or a heteroaryl group such as a pyrimidinyl or, preferably, a pyridyl group, which latter two groups are optionally substituted by one or two A groups;

at least one of R³ and R⁴ represents optionally substituted aryl or heteroaryl,

20 and up to one other represents G¹ or, more preferably, hydrogen;

when R³ or R⁴ represents an aryl or heteroaryl group, then the other substituents on the essential benzene ring in the compound of formula I (i.e. R², R⁵ and R³ or R⁴ (as appropriate)) independently represent H or G¹ (e.g. halo (such as chloro), cyano, methyl, methoxy, trifluoromethyl or

25 trifluoromethoxy);

A represents G¹;

G¹ represents cyano, halo (e.g. bromo, fluoro or, more particularly, chloro) or, more preferably, -NO₂ or -A¹-R⁷;

A¹ represents -C(O)A²- or, more preferably, a single bond, -S(O)₂A³-,

30 -N(R⁸)A⁴- or -OA⁵-;

A^2 represents $-N(R^8)-$;

A^3 represents a single bond;

A^4 represents a single bond or $-C(O)-$;

A^5 represents a single bond;

5 R^7 represents hydrogen, optionally branched, optionally unsaturated and/or optionally cyclic C_{1-6} alkyl, or a heterocycloalkyl group (such as a nitrogen-containing heterocycloalkyl group optionally containing one or two double bonds, so forming for example a piperidinyl, pyrrolidinyl, morpholinyl group or, more preferably a piperazinyl group), which latter two groups are 10 optionally substituted by one or more substituents selected from G^3 ;

R^8 represents hydrogen or C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from G^3 ;

G^3 represents halo (especially fluoro) or $-A^{11}-R^{11}$;

A^{11} represents a single bond, $-C(O)A^{12}$, $-N(R^{12})-$ or $-O-$;

15 A^{12} represents $-O-$ or $-N(R^{12})-$;

R^{11} represents hydrogen or C_{1-3} alkyl (such as methyl or ethyl); or

20 R^{11} and R^{12} are linked to form a 5- to 6-membered ring optionally containing one further heteroatom (further to the nitrogen atom to which R^{11} and R^{12} are attached), for example a nitrogen heteroatom, and which ring is optionally substituted by a C_{1-3} alkyl (e.g. methyl) group.

Especially preferred compounds of the invention are wherein:

R^6 represents H;

25 R^1 represents a phenyl group, optionally substituted, for example by halo (e.g. chloro), $-A^1-R^7$ or $-NO_2$ (e.g. optionally substituted, for example in the 4-position, by a $-A^1-R^7$ or a $-NO_2$ group and optionally further substituted, for example in the 3-position, by a $-NO_2$ group). In such instances, A^1 may represent $-OA^5-$, a single bond or a $-S(O)_2A^3-$ group. When A^1 represents $-OA^5-$, A^5 is preferably a single bond and R^7 is preferably C_{1-6} alkyl, such as 30 cyclopropyl, cyclopentyl or, more particularly, methyl, ethyl, isopropyl,

isobutyl, *t*-butyl or cyclobutylmethyl, optionally substituted by one or more G³ groups. In such instances G³ may represent halo (especially fluoro) or -A¹¹-R¹¹, wherein A¹¹ preferably represents -C(O)A¹², -OA¹⁵- or -N(R¹²)A¹⁴-, in which A¹⁴ and A¹⁵ are preferably single bonds and A¹² is 5 preferably -O- or -N(R¹²)-. In the instance when A¹¹ represents -OR¹¹-, R¹¹ is preferably H, when A¹¹ represents -N(R¹²)R¹¹, R¹¹ and R¹² are preferably linked to form a 5-membered ring, such as a pyrrolidine ring, when A¹¹ represents -C(O)OR¹¹, R¹¹ is preferably H and when A¹¹ represents -C(O)N(R¹²)R¹¹, then R¹¹ and R¹² are preferably linked to form a 6-10 membered ring, optionally containing a further nitrogen heteroatom, such as a piperazine ring, which ring is optionally substituted by a C₁₋₂ alkyl, such as a methyl, group. When A¹ represents a single bond, R⁷ may represent a C₁₋₆ (e.g. C₁₋₃) alkyl group, such as a cyclohexyl or, more particularly, a 15 methyl or ethylene group, both of which are optionally substituted by one or more G³ group. In such instances, G³ may represent halo (especially fluoro), or a -A¹¹-R¹¹ group, wherein A¹¹ is preferably a -C(O)A¹²- group, in which A¹² preferably represents -O- and R¹¹ is preferably H. When A¹ represents -S(O)₂A³-, A³ is preferably a single bond and R⁷ may represent a C₁₋₃ alkyl group, such as ethyl or, preferably, 20 methyl, or R⁷ may also represent a heterocycloalkyl group, such as a piperazine group, optionally substituted by G³, wherein G³ is preferably -A¹¹-R¹¹, A¹¹ is preferably a single bond and R⁷ may represent a C₁₋₂ alkyl group, such as a methyl group. Thus R¹ may represent a 4-cyclopropoxymethyl, 4-cyclopentoxymethyl, 4-cyclopentoxy-3-nitrophenyl, 25 4-isopropoxy-3-nitrophenyl, 4-chlorophenyl, 3,5-dichlorophenyl, 4-cyclohexylphenyl or, more particularly, 4-isopropoxyphenyl, 4-ethoxyphenyl, 4-isobutoxyphenyl, 4-cyclobutylmethoxyphenyl, 4-methoxy-phenyl, 4-(2-methyl-1-(pyrrolidin-1-yl)propan-2-yloxy)phenyl, 4-(1-hydroxy-2-methylpropan-2-yloxy)phenyl, 4-trifluoromethoxyphenyl, 4-methylsulfonylphenyl, 30 4-methyl-3-nitrophenyl, 4-trifluoromethylphenyl, 4-(2-carboxypropan-2-

yloxy)phenyl, 4-(2-carboxyvinyl)phenyl, 4-nitro-phenyl, 4-(2-methyl-1-(4-methylpiperazin-1-yl)propan-2-yloxy)phenyl, 4-(4-methylpiperazin-1-ylsulfonyl)phenyl or a phenyl group;

R¹ may also be a 2-naphthyl group, optionally substituted, for example in the 6-position by a single -A¹-R⁷ group. In such instances, A¹ may represent -OA⁵-, in which A⁵ is a single bond and R⁷ represents C₁₋₃ alkyl, such as an optionally branched propyl group, so forming, for example a 6-isopropoxynaphthalen-2-yl or 2-naphthyl group;

R¹ may also be a quinolinyl (e.g. 3-quinolinyl) group;

10 R¹ may alternatively represent a 2- or 3-pyridyl group, substituted at the *meta* or, preferably, *para*-position relative to the point of attachment of the R¹ group to the indole ring with a single substituent selected from -A¹-R⁷.

In such instances, A¹ may represent -N(R⁸)A⁴- or, more particularly, -OA⁵- or a single bond. When A¹ represents -OA⁵-, A⁵ is preferably a single bond

15 and R⁷ may represent C₁₋₅ (e.g. C₁₋₃) alkyl, such as cyclopentyl or, more particularly, ethyl or isopropyl. When A¹ represents a single bond, R⁷ may represent C₁₋₃ alkyl, such as ethyl or, preferably, methyl, which group is optionally substituted by G³, in which G³ is halo (e.g. fluoro) or, particularly, -OR¹¹ and R¹¹ may represent C₁₋₃ alkyl, such as ethyl. When 20 A¹ represents -N(R⁸)A⁴-, A⁴ is preferably a single bond, R⁸ is preferably hydrogen and R⁷ may represent C₁₋₆ alkyl, such as cyclic C₃₋₅ alkyl (e.g. cyclopentyl). Thus R¹ may also represent a 6-cyclopentoxypyrid-3-yl, 5-cyclopentylaminopyrid-2-yl, 5-trifluoromethylpyrid-2-yl or, more particularly, a 5-ethoxymethylpyrid-2-yl or 6-isopropoxypyrid-3-yl group;

25 when R² represents G¹, G¹ represents halo (e.g. chloro), cyano, methyl, trifluoromethyl or, more preferably, -NO₂ or -A¹-R⁷, in which A¹ is -N(R⁸)A⁴-. In such instances, A⁴ may represent a single bond or a -C(O)- group, R⁸ represents H and R⁷ represents H or C₁₋₃ alkyl, such as methyl. In this respect, R² may represent H, -N(H)C(O)Me or -NH₂;

R³ represents H or a phenyl group optionally substituted by one or more (e.g. two) groups selected from halo (e.g. chloro) and -A¹-R⁷ (e.g. substituted at the 3- or, more particularly, 4-position by a single -A¹-R⁷ group). In such instances, A¹ may represent -C(O)A²-, in which case A² represents -N(R⁸)- and R⁷ and R⁸ independently represent hydrogen, or A¹ may, more preferably, represent a single bond or -OA⁵-, in which A⁵ is a single bond, and R⁷ represents C₁₋₆ alkyl, such as methyl, isopropyl, *t*-butyl or hexyl (especially cyclohexyl) optionally substituted by one or more G³ groups in which G³ is halo, such as fluoro, to form, for example, a 4-chlorophenyl, 3,5-dichlorophenyl, 2,4-dichlorophenyl, 4-carbamoylphenyl group or, more particularly, a 4-*tert*-butylphenyl, 4-isopropoxyphenyl, 4-trifluoromethylphenyl, 4-trifluoromethoxyphenyl or 4-cyclohexylphenyl group;

R³ may alternatively represent a 2- or 3-pyridyl group, substituted at the *meta* or, preferably, *para*-position relative to the point of attachment of the R³ group to the indole ring with a single substituent selected from halo (e.g. chloro) or, more preferably, -A¹-R⁷. In such instances, A¹ may represent -N(R⁸)A⁴-, in which A⁴ represents a single bond, R⁸ represents hydrogen and R⁷ represents C₁₋₆ alkyl, such as cyclic C₃₋₅ alkyl (e.g. cyclopentyl) or, A¹ may, more particularly represent a single bond or -OA⁵-, in which A⁵ is a single bond and R⁷ represents a heterocycloalkyl (such as a 5-membered nitrogen containing heterocycloalkyl ring optionally containing a double bond (e.g. 3,4,5,6-tetrahydro-2H-pyridyl)) or, more particularly a C₁₋₅ (e.g. C₁₋₃) alkyl, such as cyclopentyl or, more particularly, methyl or isopropyl optionally substituted by one or more G³ groups in which G³ is halo such as fluoro, to form for example a 5-chloropyrid-2-yl, 5-cyclopentylaminopyrid-2-yl, 6-cyclopentoxypyrid-3-yl, 6-(piperidin-1-yl)pyridin-3-yl or, more particularly, a 5-trifluoromethylpyrid-2-yl or 6-isopropoxypyrid-3-yl group;

R³ may alternatively represent pyrimidinyl group (e.g. 2-pyrimidinyl), optionally substituted, for example at the *meta* or, more particularly, *para*

position relative to the point of attachment of the R^3 group to the indole ring, with a single substituent selected from halo (e.g. bromo) and $-A^1-R^7$, in which A^1 preferably represents a single bond and R^7 represents C_{1-3} alkyl (e.g. propyl) or a heteroaryl group, for example a nitrogen-containing heteroaryl group such as pyridyl (e.g. 2-pyridyl). Thus R^3 may also represent 5-bromopyrimidin-2-yl, 5-propylpyrimidin-2-yl or 5-(pyridin-2-yl)pyrimidin-2-yl;

R^4 represents H, a pyridyl group or a phenyl group, which latter group may be substituted at the 3- or, more particularly, 4-position with a single $-A^1-R^7$

10 group. In such instances, A^1 may represent $-OA^5-$, in which A^5 is a single bond and R^7 represents C_{1-4} alkyl, such as isopropyl, optionally substituted by one or more G^3 groups in which G^3 is halo, such as fluoro, so forming, for example, a 4-isopropoxyphenyl group;

R^5 represents H.

15

Particularly preferred compounds of the invention include those of the examples described hereinafter.

20 Compounds of the invention may be made in accordance with techniques that are well known to those skilled in the art, for example as described hereinafter.

According to a further aspect of the invention there is provided a process for the preparation of a compound of formula I, which process comprises:


25

(i) for compounds of formula I wherein X represents halo, reaction of a compound of formula I wherein X represents H, with a reagent or mixture of reagents known to be a source of halide ions. For example, for bromide ions, *N*-bromosuccinimide may be employed, for iodide ions, iodine or a mixture of NaI and *N*-chlorosuccinimide may be employed, for chloride

ions, *N*-chlorosuccinimide may be employed and for fluoride ions, 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) may be employed. This reaction may be carried out in a suitable solvent (e.g. acetone, benzene or dioxane) under conditions known to the
5 skilled person;

(ii) for compounds of formula I wherein X represents H, reaction of a compound of formula II,

10



wherein R², R³, R⁴, R⁵ and R⁶ are as hereinbefore defined, with a compound of formula III,


15



wherein L¹ represents a suitable leaving group such as as chloro, bromo, iodo, a sulfonate group (e.g. -OS(O)₂CF₃, -OS(O)₂CH₃, -OS(O)₂PhMe or a nonaflate) or -B(OH)₂ and R¹ is as hereinbefore defined, for example
20 optionally in the presence of an appropriate metal catalyst (or a salt or complex thereof) such as Cu, Cu(OAc)₂, CuI (or CuI/diamine complex), Pd(OAc)₂, Pd₂(dba)₃ or NiCl₂, and an optional additive such as Et₃N, pyridine, *N,N'*-dimethylethylenediamine, Ph₃P, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, xantphos, NaI or an appropriate crown ether
25 such as 18-crown-6-benzene, in the presence of an appropriate base such as NaH, Et₃N, pyridine, *N,N'*-dimethylethylenediamine, Na₂CO₃, K₂CO₃,

K₃PO₄, Cs₂CO₃, *t*-BuONa or *t*-BuOK (or a mixture thereof), in a suitable solvent (e.g. dichloromethane, dioxane, toluene, ethanol, isopropanol, dimethylformamide, ethylene glycol, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, *N*-methylpyrrolidinone, tetrahydrofuran or a mixture thereof) or in the absence of an additional solvent when the reagent may itself act as a solvent (e.g. when R¹ represents phenyl and L¹ represents bromo, i.e. bromobenzene). This reaction may be carried out at room temperature or above (e.g. at a high temperature, such as the reflux temperature of the solvent system that is employed) or using microwave irradiation;

(iii) for compounds of formula I wherein X represents H, reaction of a compound of formula IV,



wherein L³ represents L¹ or L², in which L² represents a suitable leaving group such as chloro, bromo, iodo, -B(OH)₂ or a protected derivative thereof, for example a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, 9-borabicyclo[3.3.1]nonane (9-BBN), -Sn(alkyl)₃ (e.g. -SnMe₃ or -SnBu₃), or a similar group known to the skilled person, and L³ is attached to one or more of the carbon atoms of the benzenoid ring of the indole, and the remaining positions of the benzenoid ring are substituted with 1 to 3 (depending on the number of L³ substituents) R²-R⁵ substituents, R²-R⁵ represents any one of the substituents, i.e. R², R³, R⁴ and R⁵, that are already present in that ring (as appropriate), and L¹, R¹, R², R³, R⁴, R⁵ and R⁶ are as hereinbefore defined, with a compound of formula V,



wherein R^{20} represents R^2 , R^3 , R^4 or R^5 (as appropriate), and L^4 represents 5 L^1 (when L^3 represents L^2) or L^2 (when L^3 represents L^1), as hereinbefore defined. The skilled person will appreciate that L^1 and L^2 will be mutually compatible. This reaction may be performed, for example in the presence of a suitable catalyst system, e.g. a metal (or a salt or complex thereof) such as CuI , $PdCl_2$, Pd/C , $Pd(OAc)_2$, $Pd(Ph_3P)_2Cl_2$, $Pd(Ph_3P)_4$, $Pd_2(dba)_3$ or $NiCl_2$ 10 and an additive such as $t\text{-}Bu_3P$, $(C_6H_{11})_3P$, Ph_3P , $AsPh_3$, $P(o\text{-}Tol)_3$, 1,2-bis(diphenylphosphino)ethane, 2,2'-bis(di-*tert*-butylphosphino)-1,1'-biphenyl, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 1,1'-bis(diphenylphosphinoferrocene), 1,3-bis(diphenyl-phosphino)propane or xantphos, together with a suitable base such as, Na_2CO_3 , K_3PO_4 , Cs_2CO_3 , KOH , 15 $NaOH$, K_2CO_3 , CsF , Et_3N , $(i\text{-}Pr)_2NEt$, $t\text{-}BuONa$ or $t\text{-}BuOK$ (or mixtures thereof) in a suitable solvent such as dioxane, toluene, ethanol, dimethylformamide, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, *N*-methylpyrrolidinone, tetrahydrofuran or mixtures thereof. The reaction may be carried out for 20 example at room temperature or above (e.g. at a high temperature such as the reflux temperature of the solvent system) or using microwave irradiation. The skilled person will appreciate that when L^3 or L^4 (of the compounds of formulae IV and V, respectively, represent halo, such compounds may first be activated by:

25 (I) forming the corresponding Grignard reagent under standard conditions known to those skilled in the art (e.g. employing magnesium or a suitable reagent such as a mixture of C_{1-6} alkyl-Mg-halide and $ZnCl_2$ or $LiCl$), followed by reaction with a compound of formula IV or V (as appropriate), optionally in the presence of a


catalyst (e.g. FeCl_3) under conditions known to those skilled in the art; or

5 (II) forming the corresponding lithiated compound under halogen-lithium exchange reaction conditions known to those skilled in the art (e.g. employing $n\text{-BuLi}$ or $t\text{-BuLi}$ in the presence of a suitable solvent (e.g. a polar aprotic solvent, such as THF)), followed by reaction with a compound of formula IV or V (as appropriate).

10 The skilled person will also appreciate that the magnesium of the Grignard reagent or the lithium of the lithiated species may be exchanged for a different metal (i.e. a transmetallation reaction may be performed), for example to zinc (e.g. using ZnCl_2) and the intermediate so formed may then be subjected to reaction with a compound of formula IV or V (as appropriate) under conditions known to those skilled in the art, for example such as those described above;

15

Compounds of formula II, may be prepared by reaction of a compound of formula VI,



20

wherein L^3 , $\text{R}^2\text{-R}^5$ and R^6 are as hereinbefore defined with a compound of formula V as hereinbefore defined, for example under conditions such as those described hereinbefore in respect of preparation of compounds of formula I (process step (iii)) above.

25.

Compounds of formula IV, may be prepared by reaction of a compound of formula VI with a compound of formula III as hereinbefore defined, for

example under reaction conditions such as those described hereinbefore in respect of preparation of compounds of formula I (process step (ii)) above.

Compounds of formula IV in which L^3 represents L^2 may be prepared by 5 reaction of a compound of formula IV in which L^3 represents L^1 , with an appropriate reagent for the introduction of the L^2 group. This conversion may be performed by methods known to those skilled in the art, for example:

i) compounds of formula IV, in which L^3 is 4,4,5,5-tetramethyl-1,3,2-

10 dioxaborolan-2-yl may be prepared by reaction of the reagent bis(pinacolato)diboron with a compound of formula IV in which L^3 represents L^1 , for example under reaction conditions such as those described hereinbefore in respect of preparation of compounds of formula I (process step (ii)) above;

15 ii) compounds of formula IV, in which L^3 represents $-B(OH)_2$ may be prepared by reaction of a corresponding compound of formula IV in

which L^3 represents halo by reaction with, for example, boronic acid or a protected derivative thereof (e.g. bis(pinacolato)diboron or triethyl borate) followed by (if necessary) deprotection under

20 standard conditions. The skilled person will appreciate that the compound of formula IV in which L^3 represents halo may first need to be converted to the corresponding Grignard reagent, or another metal (e.g. *via* a transmetallation reaction), for example under conditions such as those described in respect of preparation of

25 compounds of formula I (process step (iii)) above; or

(iii) compounds of formula IV in which L^3 represents a halo group may be prepared by reaction of a corresponding compound of formula IV in which L^3 represents a different halo group, for example employing a suitable source of halide ions such as those described hereinbefore 30 in respect of preparation of compounds of formula I (process step (i))

above, under conditions known to those skilled in the art. For example, conversion of a bromo group to an iodo group may be performed in the presence of NaI, optionally in the presence of a suitable catalyst (e.g. CuI) and/or a catalytic amount of base (e.g. 5 *N,N*-dimethyl-1,2-diaminoethane) in the presence of a suitable solvent such as one described hereinbefore in respect of preparation of compounds of formula I (process step (i)) above.

Conversions of the L⁴ group and the L³ group in the compounds of formulae 10 V and VI, respectively, may be performed in a similar manner to that described above in respect of converting the L³ group in compounds of formula IV.

Compounds equivalent to compounds of formula II, IV and VI, but which 15 are substituted in the 3-position with a halo group may be prepared by reaction of a corresponding compound of formula II, IV and VI, respectively, with a reagent known to be a source of halide ions, for example under conditions such as those hereinbefore described in respect of preparation of compounds of formula I (process step (i)) above.


20 Compounds of formulae III, V, and VI are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using 25 appropriate reagents and reaction conditions. In this respect, the skilled person may refer to *inter alia* "Comprehensive Organic Synthesis" by B. M. Trost and I. Fleming, Pergamon Press, 1991.

Indoles of formulae II, IV and VI, may also be prepared with reference to a 30 standard heterocyclic chemistry textbook (e.g. "Heterocyclic Chemistry" by

J. A. Joule, K. Mills and G. F. Smith, 3rd edition, published by Chapman & Hall or "Comprehensive Heterocyclic Chemistry II" by A. R. Katritzky, C. W. Rees and E. F. V. Scriven, Pergamon Press, 1996) and/or made according to the following general procedures.

5

For example compounds of formulae II and VI, may be prepared by reaction of a compound of formula VII,




10

wherein SUB represents the substitution pattern that is present in the compound of formula II or VI to be formed and R⁶ is as hereinbefore defined, under standard Fischer indole synthesis conditions known to the person skilled in the art.

15

Compounds of formulae II and VI, may alternatively be prepared by reaction of a compound of formula VIII,



20

wherein SUB is as hereinbefore defined with a compound of formula IX,




wherein R^6 is as hereinbefore defined and preferably does not represent hydrogen, under conditions, known to the person skilled in the art (i.e. to induce a condensation reaction, followed by a thermally induced cyclisation).

5

Compounds of formula VII, may be prepared by:


(a) reaction of a compound of formula X,

10



wherein SUB is as hereinbefore defined with a compound of formula XI,

15




wherein R^6 is as hereinbefore defined under conditions known to the skilled person; or


20

(b) reaction of a compound of formula XII,

25



wherein SUB is as hereinbefore defined with a compound of formula XIII,



wherein R^m represents OH, O-C₁₋₆ alkyl or C₁₋₆ alkyl and R⁶ is as hereinbefore defined, for example under Japp-Klingemann conditions known to the skilled person.

5

Compounds of formulae VIII, IX, X, XI, XII, XIII are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic 10 procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions. In this respect, the skilled person may refer to *inter alia* "Comprehensive Organic Synthesis" by B. M. Trost and I. Fleming, Pergamon Press, 1991.

15 The substituents R¹, R², R³, R⁴, R⁵, R⁶ and X in final compounds of the invention or relevant intermediates may be modified one or more times, after or during the processes described above by way of methods that are well known to those skilled in the art. Examples of such methods include substitutions, reductions, oxidations, alkylations, hydrolyses, esterifications, 20 and etherifications. The precursor groups can be changed to a different such group, or to the groups defined in formula I, at any time during the reaction sequence. For example, in cases where R⁶ does not initially represent hydrogen (so providing an ester functional group), the skilled person will appreciate that at any stage during the synthesis (e.g. the final 25 step), the relevant substituent may be hydrolysed to form a carboxylic acid functional group (in which case R⁶ will be hydrogen). Further, halo groups (e.g. of a compound of formula I when X represents halo) may be converted to other halo groups, for example as described hereinbefore. In this respect,

the skilled person may also refer to "*Comprehensive Organic Functional Group Transformations*" by A. R. Katritzky, O. Meth-Cohn and C. W. Rees, Pergamon Press, 1995.

5 Compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

It will be appreciated by those skilled in the art that, in the processes described above and hereinafter, the functional groups of intermediate 10 compounds may need to be protected by protecting groups.

The protection and deprotection of functional groups may take place before or after a reaction in the above-mentioned schemes.

15 Protecting groups may be removed in accordance with techniques that are well known to those skilled in the art and as described hereinafter. For example, protected compounds/intermediates described herein may be converted chemically to unprotected compounds using standard deprotection techniques.

20 The type of chemistry involved will dictate the need, and type, of protecting groups as well as the sequence for accomplishing the synthesis.

25 The use of protecting groups is fully described in "*Protective Groups in Organic Chemistry*", edited by J W F McOmie, Plenum Press (1973), and "*Protective Groups in Organic Synthesis*", 3rd edition, T.W. Greene & P.G.M. Wutz, Wiley-Interscience (1999).

Medical and Pharmaceutical Uses

Compounds of the invention are indicated as pharmaceuticals. According to a further aspect of the invention there is provided a compound of the invention, as hereinbefore defined but without the proviso, for use as a pharmaceutical.

Although compounds of the invention may possess pharmacological activity as such, certain pharmaceutically-acceptable (e.g. "protected") derivatives of compounds of the invention may exist or be prepared which may not possess such activity, but may be administered parenterally or orally and thereafter be metabolised in the body to form compounds of the invention. Such compounds (which may possess some pharmacological activity, provided that such activity is appreciably lower than that of the "active" compounds to which they are metabolised) may therefore be described as "prodrugs" of compounds of the invention.

By "prodrug of a compound of the invention", we include compounds that form a compound of the invention, in an experimentally-detectable amount, within a predetermined time (e.g. about 1 hour), following oral or parenteral administration. All prodrugs of the compounds of the invention are included within the scope of the invention.

Furthermore, certain compounds of the invention (including, but not limited to, compounds of formula I in which R⁶ is other than hydrogen) may possess no or minimal pharmacological activity as such, but may be administered parenterally or orally, and thereafter be metabolised in the body to form compounds of the invention that possess pharmacological activity as such (including, but not limited to, corresponding compounds of formula I, in which R⁶ represents hydrogen). Such compounds (which also

includes compounds that may possess some pharmacological activity, but that activity is appreciably lower than that of the "active" compounds of the invention to which they are metabolised), may also be described as "prodrugs".

5

Thus, the compounds of the invention are useful because they possess pharmacological activity, and/or are metabolised in the body following oral or parenteral administration to form compounds which possess pharmacological activity.

10

Compounds of the invention are particularly useful because they may inhibit (for example selectively) the activity of prostaglandin E synthases (and particularly microsomal prostaglandin E synthase-1 (mPGES-1)), i.e. they prevent the action of mPGES-1 or a complex of which the mPGES-1 enzyme forms a part, and/or may elicit a mPGES-1 modulating effect, for example as may be demonstrated in the test described below. Compounds of the invention may thus be useful in the treatment of those conditions in which inhibition of a PGES, and particularly mPGES-1, is required.

15

Compounds of the invention may inhibit the activity of leukotriene C₄ (LTC₄), for example as may be shown in a test such as that described in *Eur. J. Biochem.*, 208, 725-734 (1992), and may thus be useful in the treatment of those conditions in which inhibition of LTC₄ is required.

20

Compounds of the invention may also inhibit the activity of 5-lipoxygenase-activating protein (FLAP), for example as may be shown in a test such as that described in *Mol. Pharmacol.*, 41, 873-879 (1992).

Compounds of the invention are thus expected to be useful in the treatment of inflammation.

25

30

The term "inflammation" will be understood by those skilled in the art to include any condition characterised by a localised or a systemic protective response, which may be elicited by physical trauma, infection, chronic diseases, such as those mentioned hereinbefore, and/or chemical and/or 5 physiological reactions to external stimuli (e.g. as part of an allergic response). Any such response, which may serve to destroy, dilute or sequester both the injurious agent and the injured tissue, may be manifest by, for example, heat, swelling, pain, redness, dilation of blood vessels and/or increased blood flow, invasion of the affected area by white blood 10 cells, loss of function and/or any other symptoms known to be associated with inflammatory conditions.

The term "inflammation" will thus also be understood to include any inflammatory disease, disorder or condition *per se*, any condition that has 15 an inflammatory component associated with it, and/or any condition characterised by inflammation as a symptom, including *inter alia* acute, chronic, ulcerative, specific, allergic and necrotic inflammation, and other forms of inflammation known to those skilled in the art. The term thus also includes, for the purposes of this invention, inflammatory pain, pain 20 generally and/or fever.

Accordingly, compounds of the invention may be useful in the treatment of inflammatory bowel disease, irritable bowel syndrome, migraine, headache, low back pain, fibromyalgia, myofascial disorders, viral infections (e.g. 25 hepatitis C and, particularly, influenza, common cold, herpes zoster, and AIDS), bacterial infections, fungal infections, dysmenorrhea, burns, surgical or dental procedures, malignancies (e.g. breast cancer, colon cancer, and prostate cancer), atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, fever (e.g. rheumatic fever), ankylosing 30 spondylitis, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis,

bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, neurodegenerative disorders such as Alzheimer's disease and multiple sclerosis, autoimmune diseases, osteoporosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, allergic disorders, rhinitis, ulcers, coronary heart disease, sarcoidosis and any other disease with an inflammatory component. Other diseases that may be mentioned include inflammatory pain, hyperprostaglandin E syndrome, classic Bartter syndrome, Hodgkin's disease and persistent ductus (PDA).

10

Compounds of the invention may also have effects that are not linked to inflammatory mechanisms, such as in the reduction of bone loss in a subject. Conditions that may be mentioned in this regard include osteoporosis, osteoarthritis, Paget's disease and/or periodontal diseases.

15

Compounds the invention may thus also be useful in increasing bone mineral density, as well as the reduction in incidence and/or healing of fractures, in subjects.

20

Compounds of the invention are indicated both in the therapeutic and/or prophylactic treatment of the above-mentioned conditions.

25

According to a further aspect of the present invention, there is provided a method of treatment of a disease which is associated with, and/or which can be modulated by inhibition of LTC₄, FLAP and/or, preferably, a PGES (such as mPGES-1), and/or a method of treatment of a disease in which inhibition of the activity of LTC₄, FLAP and/or, preferably, a PGES (and particularly mPGES-1) is desired and/or required (e.g. inflammation), which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined but without the proviso, to a patient suffering from, or susceptible to, such a condition.

30

“Patients” include mammalian (including human) patients.

5 The term “effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated patient. The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect).

10 Compounds of the invention will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, by any other parenteral route or *via* inhalation, in a pharmaceutically acceptable dosage form.

15 Compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.

20 Such formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice.

25 According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the proviso, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

30 Compounds of the invention may also be combined with other therapeutic agents that are useful in the treatment of inflammation (e.g. NSAIDs and coxibs).

According to a further aspect of the invention, there is provided a combination product comprising:

(A) a compound of the invention, as hereinbefore defined but without the proviso; and

(B) another therapeutic agent that is useful in the treatment of inflammation,

wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

10

Such combination products provide for the administration of a compound of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent).

Thus, there is further provided:

20

(1) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the proviso, another therapeutic agent that is useful in the treatment of inflammation, and a pharmaceutically-acceptable adjuvant, diluent or carrier; and

25

(2) a kit of parts comprising components:

(a) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the proviso, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of inflammation in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable
5 for administration in conjunction with the other.

Compounds of the invention may be administered at varying doses. Oral, pulmonary and topical dosages may range from between about 0.01 mg/kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably
10 about 0.01 to about 10 mg/kg/day, and more preferably about 0.1 to about 5.0 mg/kg/day. For e.g. oral administration, the compositions typically contain between about 0.01 mg to about 500 mg, and preferably between about 1 mg to about 100 mg, of the active ingredient. Intravenously, the most preferred doses will range from about 0.001 to about 10 mg/kg/hour
15 during constant rate infusion. Advantageously, compounds may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

In any event, the physician, or the skilled person, will be able to determine
20 the actual dosage which will be most suitable for an individual patient, which is likely to vary with the route of administration, the type and severity of the condition that is to be treated, as well as the species, age, weight, sex, renal function, hepatic function and response of the particular patient to be treated. The above-mentioned dosages are exemplary of the
25 average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Compounds of the invention may have the advantage that they are effective,
30 and preferably selective, inhibitors of prostaglandin E synthases (PGES)

and particularly microsomal prostaglandin E synthase-1 (mPGES-1). The compounds of the invention may reduce the formation of the specific arachidonic acid metabolite PGE₂ without reducing the formation of other COX generated arachidonic acid metabolites, and thus may not give rise to 5 the associated side-effects mentioned hereinbefore.

Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, 10 and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the above-stated indications or otherwise.

15 Biological Test

In the assay human mPGES-1 catalyses the reaction where the substrate PGH₂ is converted to PGE₂. mPGES-1 is expressed in *E. coli* and the membrane fraction is dissolved in 20mM NaPi-buffer pH 8.0 and stored at -80 °C. In the assay human mPGES-1 is dissolved in 0.1 M KPi-buffer pH 20 7.35 with 2.5 mM glutathione. The stop solution consists of H₂O / MeCN (7/3), containing FeCl₂ (25 mM) and HCl (0.15 M). The assay is performed at room temperature in 96-well plates. Analysis of the amount of PGE₂ is performed with reversed phase HPLC (Waters 2795 equipped with a 3.9 x 25 150 mm C18 column). The mobile phase consists of H₂O / MeCN (7/3), containing TFA (0.056%), and absorbance is measured at 195 nm with a Waters 2487 UV-detector.

The following is added chronologically to each well:

1. 100 µL human mPGES-1 in KPi-buffer with glutathione. Total protein concentration: 0.02 mg/mL.

2. 1 μ L inhibitor in DMSO. Incubation of the plate at room temperature for 25 minutes.
3. 4 μ L of a 0.25 mM PGH₂ solution. Incubation of the plate at room temperature for 60 seconds.
- 5 4. 100 μ L stop solution.
180 μ L per sample is analyzed with HPLC.

Examples

10 The invention is illustrated by way of the following examples, in which the following abbreviations may be employed:

dba	dibenzylideneacetone
DIBAL	diisobutylaluminium hydride
DMAP	4,4-dimethylaminopyridine
15 DMF	dimethylformamide
DMSO	dimethylsulfoxide
EtOAc	ethyl acetate
HPLC	High Pressure Liquid Chromatography
MeCN	acetonitrile
20 MS	mass spectrum
NMR	nuclear magnetic resonance
TFA	trifluoroacetic acid
THF	tetrahydrofuran
xantphos	9,9-dimethyl-4,5-bis(diphenylphosphino)-
25	xanthene

Starting materials and chemical reagents specified in the syntheses described below are commercially available from, *e.g.* Sigma-Aldrich Fine Chemicals.

The term "light petrol" when used herein refers to petroleum ether (40-60°C).

5 Example 1

5-(4-*tert*-Butylphenyl)-1-(4-isopropoxypyphenyl)-indole-2-carboxylic acid

(a) 5-(4-*tert*-Butylphenyl)indole-2-carboxylic acid ethyl ester

A mixture of 5-bromoindole-2-carboxylic acid ethyl ester (3.48 g, 13 mmol), 4-*tert*-butylphenylboronic acid (4.63 g, 26 mmol), K₃PO₄ (9.93 g, 45 mmol), Pd(OAc)₂ (146 mg, 0.65 mmol), tri-*o*-tolylphosphine (396 mg, 1.3 mmol), EtOH (20 ml) and toluene (10 mL) was stirred under argon for 20 min at room temperature, and then heated at 100°C for 24 h. The mixture was allowed to cool, poured into NaHCO₃ (aq., sat.) and extracted with EtOAc. The combined extracts were washed with water and brine and then dried over Na₂SO₄. Concentration and purification by chromatography gave the sub-title compound (3.27 g, 78%).

(b) 5-(4-*tert*-Butylphenyl)-1-(4-isopropoxypyphenyl)indole-2-carboxylic acid

20 ethyl ester

5-(4-*tert*-Butylphenyl)indole-2-carboxylic acid ethyl ester (198 mg, 0.60 mmol; see step (a) above), CuI (12 mg, 0.06 mmol), K₃PO₄ (254 mg, 1.2 mmol), *N,N*-dimethyl-1,2-diaminoethane (20 μL, 0.18 mmol) and 1-bromo-4-isopropoxybenzene (258 mg, 1.2 mmol) in toluene (2 mL) was heated at 25 110°C for 17 h. The mixture was diluted with EtOAc and washed with NaHCO₃ (aq. sat.), HCl (aq. 0.1 M), brine and then dried over Na₂SO₄. Concentration and purification by chromatography gave the sub-title compound (260 mg, 94%).

(c) 5-(4-*tert*-Butylphenyl)-1-(4-isopropoxypyphenyl)-indole-2-carboxylic acid

A mixture of 5-(4-*tert*-butylphenyl)-1-(4-isopropoxypyphenyl)-indole-2-carboxylic acid ethyl ester (259 mg, 0.57 mmol; see step (b)), NaOH (114 mg, 2.85 mmol), water (0.6 mL) and dioxane (3 mL) was heated using microwave irradiation for 1 h at 120°C. An additional portion of NaOH (100 mg) was added and heating was continued for another 30 min at 120°C. After cooling, the reaction was acidified with HCl (1M) to pH 2 and extracted with EtOAc. The combined extracts were washed with water, brine and dried over Na₂SO₄ and purified by chromatography to give the title compound (165 mg, 60%).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 7.96 (1H, s), 7.62-7.50 (3H, m), 7.49-7.36 (3H, m), 7.30-7.20 (2H, m), 7.10-6.96 (3H, m), 4.67 (1H, septet, J=6.0 Hz), 1.32 (6H, d, J=6.0 Hz), 1.30 (9H, s).

15 Example 21.6-Bis(4-isopropoxypyphenyl)-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1, using 6-bromoindole-2-carboxylic acid ethyl ester, 4-isopropoxypyphenylboronic acid and 4-bromo-1-isopropoxypybenzene.

20 200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 7.77 (1H, d, J=8.3 Hz), 7.50-7.22 (6H, m), 7.11-6.87 (5H, m), 4.67 (1H, septet, J=6.0 Hz), 4.59 (1H, septet, J=6.0 Hz), 1.31 (6H, d, J=6.0 Hz), 1.24 (6H, d, J=6.0 Hz).

Example 31.5-Bis(4-isopropoxypyphenyl)-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1, using 5-bromoindole-2-carboxylic acid ethyl ester, 4-isopropoxypyphenylboronic acid and 4-bromo-1-isopropoxypybenzene.

20 200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.8 (1H, br s), 7.93 (1H, d, J=1.6 Hz), 7.61-7.49 (3H, m), 7.39 (1H, s), 7.31-7.22 (2H, m), 7.09-6.95 (5H, m),

4.69 (1H, septet, $J=6.0$ Hz), 4.64 (1H, septet, $J=6.0$ Hz), 1.33 (6H, d, $J=6.0$ Hz), 1.28 (6H, d, $J=6.0$ Hz).

Example 4

5 1,5-Bis(4-isopropoxyphephenyl)-4-nitroindole-2-carboxylic acid

(a) 1,5-Bis(4-isopropoxyphephenyl)indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 1(b), using 5-bromoindole-2-carboxylic acid ethyl ester, 4-isopropoxyphephenylboronic acid and 4-bromo-1-isopropoxyphephenene.

(b) 1,5-Bis(4-isopropoxyphephenyl)-4-nitroindole-2-carboxylic acid ethyl ester

15 $\text{Cu}(\text{NO}_3)_2 \times 2.5 \text{ H}_2\text{O}$ (230 mg, 0.99 mmol), whilst stirring, was added to Ac_2O (5 mL) at -5°C . This was followed by the dropwise addition of 1,5-bis(4-isopropoxyphephenyl)indole-2-carboxylic acid ethyl ester (570 mg, 1.24 mmol; see step (a)) in Ac_2O (10 mL). After 2h at room temperature, the solid was filtered off and washed with Ac_2O . The combined filtrates were poured onto ice and stirred for 18 h. The solid was collected and purified by chromatography to yield the sub-title compound (335 mg, 54%).

20

(c) 1,5-Bis(4-isopropoxyphephenyl)-4-nitroindole-2-carboxylic acid

The title compound was prepared by hydrolysis of 1,5-bis(4-isopropoxyphephenyl)-4-nitroindole-2-carboxylic acid ethyl ester in accordance with the procedure described in Example 1(c).

25 200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 13.3 (1H, br s), 7.39-7.28 (5H, m), 7.28-7.20 (2H, m), 7.09-6.93 (4H, m), 4.69 (1H, septet, $J=6.0$ Hz), 4.64 (1H, septet, $J=6.0$ Hz), 1.31 (6H, d, $J=6.0$ Hz), 1.27 (6H, d, $J=6.0$ Hz).

Example 54-Amino-1,5-bis(4-isopropoxypyhenyl)2-carboxylic acid hydrochloride

5 (a) 4-Amino-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester

A stirred mixture of 1,5-bis(4-isopropoxypyhenyl)-4-nitroindole-2-carboxylic acid ethyl ester (335 mg, 0.67 mmol; see Example 4(b)) and Pd/C (10%, 120 mg) in EtOAc was hydrogenated at ambient pressure and temperature for 10 h and filtered through Celite®. The filter cake was 10 washed with EtOAc and the combined filtrates were concentrated and purified by chromatography to yield the sub-title compound (272 mg, 86%).

15 (b) 4-Amino-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid hydrochloride

15 A mixture of 4-amino-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester (160 mg, 340 nmol; see step (a)), acetonitrile (5 mL), and aqueous NaOH (1M, 2 mL) was heated at reflux for 3 h, and then allowed to cool. The pH was adjusted to 7 with 1 M HCl, and the mixture extracted with EtOAc. The combined extracts were washed with brine, dried over 20 Na_2SO_4 , concentrated, purified by chromatography, and dissolved in Et_2O /absolute ethanol (3 mL). 4M HCl (100 μL) in dioxane was added. The precipitate was filtered off, washed with Et_2O , and dried to yield the title compound (124 mg, 86%).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 7.75-7.71 (1H, m), 7.41-7.32 (2H, m), 7.29-7.19 (2H, m), 7.12-6.96 (5H, m), 6.72-6.54 (1H, m), 4.68 (1H, septet, $J=5.7$ Hz), 4.66 (1H, septet, $J=5.7$ Hz), 1.33 (6H, d, $J=5.7$ Hz), 1.30 (6H, d, $J=5.7$ Hz).

Example 64-Acetamido-1,5-bis(4-isopropoxypyhenyl)-indole-2-carboxylic acid(a) 4-Acetamido-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethylester

A mixture of 4-amino-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester (160 mg, 0.34 mmol; see Example 5(a)), acetyl chloride (50 mg, 0.63 mmol), Et₃N (63 mg, 0.63 mmol) and MeCN (10 mL) was stirred at room temperature for 30 minutes, then poured into HCl (1M) and extracted with EtOAc. The combined extracts were washed with water and brine, and dried over Na₂SO₄. Concentration and purification by chromatography gave the sub-title compound (182 mg, 84%).

(b) 4-Acetamido-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid

The title compound (23 mg, 49%) was prepared by hydrolysis of 4-acetamido-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester (see step (a)) in accordance with the procedure described in Example 1(c).
200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.8-12.7 (1H, br s), 9.58 (1H, s) 7.33-7.20 (5H, m), 7.14 (1H, s), 7.09-7.01 (2H, m), 7.00-6.91 (3H, m), 4.70 (1H, septet, J=6.0 Hz), 4.64 (1H, septet, J=6.0 Hz), 2.01 (3H, s), 1.34 (6H, d, J=6.0 Hz), 1.29 (6H, d, J=6.0 Hz).

Example 71-(4-Isopropoxypyhenyl)-5-(4-(trifluoromethyl)phenyl)-indole-2-carboxylicacid

The title compound was prepared in accordance with Example 1, using 5-bromoindole-2-carboxylic acid ethyl ester, 4-(trifluoromethyl)phenylboronic acid and 4-bromo-1-isopropoxybenzene.

200 MHz ^1H -NMR (CDCl_3 , ppm) δ 8.01-7.94 (1H, m), 7.80 -7.66 (4H, m), 7.31-7.14 (5H, m), 7.62 -7.50 (2H, m), 4.65 (1H, septet, $J=5.8$ Hz), 1.44 (6H, d, $J=5.8$).

5 Example 8

1-(4-Isopropoxvphenyl)-5-(5-(trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid

10 (a) 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indole-2-carboxylic acid ethyl ester

A mixture prepared from $\text{Pd}_2(\text{dba})_3$ (0.229 g, 0.25 mmol), tricyclohexylphosphine (0.421 g, 1.5 mmol) and dioxane (25 mL) was added under argon to a stirred mixture of 5-bromoindole-2-carboxylic acid ethyl ester (1.94 g, 7.2 mmol), KOAc (1.10 g, 11 mmol), 15 bis(pinacolato)diboron (2.00 g, 7.9 mmol) and dioxane (25 mL) at 80 °C. After 2 h at 80°C another portion (16 mL) of the mixture prepared from $\text{Pd}_2(\text{dba})_3$, tricyclohexylphosphine and dioxane, as described herein, was added and the resulting mixture stirred at 80 °C for 16 h. The mixture was allowed to cool and filtered through Celite®. The filter cake was washed 20 with EtOAc and the combined filtrates were concentrated and purified by chromatography to yield the sub-title compound (1.10 g, 46%).

(b) 5-(5-(Trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid ethyl ester

A stirred mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-25 2-carboxylic acid ethyl ester (300 mg, 0.95 mmol; see step (a)), 2-bromo-5-(trifluoromethyl)pyridine (323 mg, 1.43 mmol), sodium carbonate (2M, 1.43 mL, 2.85 mmol), $\text{Pd}(\text{PPh}_3)_4$ (54 mg, 0.05 mmol), EtOH (5 mL) and toluene(20 mL) was heated at 80°C for 2 h. Another portion of $\text{Pd}(\text{PPh}_3)_4$ (54 mg, 0.05 mmol) was added and the heating continued for 16 h. The 30 mixture was diluted with EtOAc , washed with brine, dried over MgSO_4 ,

concentrated and purified by chromatography to give the sub-title compound (247 mg, 77%).

5 (c) 1-(4-Isopropoxypyphenyl)-5-(5-(trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid ethyl ester

Anhydrous CH_2Cl_2 (10 mL), followed by Et_3N (92 μL , 0.66 mmol), pyridine (54 μL , 0.66 mmol) and 3 \AA molecular sieves (1 g) were added to a mixture of 5-(5-(trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid ethyl ester (110 mg, 1.33 mmol; see step (b)), $\text{Cu}(\text{OAc})_2$ (120 mg, 0.66 mmol), and 4-isopropoxyphenylboronic acid (119 mg, 0.66 mmol). The mixture was stirred vigorously at ambient temperature for 18 h after which additional $\text{Cu}(\text{OAc})_2$ (59.9 mg, 0.33 mmol), 4-isopropoxyphenylboronic acid (59.4 mg, 0.33 mmol), Et_3N (46.4 μL , 0.33 mmol) and pyridine (27 μL , 0.33 mmol) were added. After a further 30 h of stirring, the mixture was 15 filtered through Celite[®]. The filter cake was washed with EtOAc and the solvents concentrated and purified by chromatography to give the sub-title compound.

20 (d) 1-(4-Isopropoxypyphenyl)-5-(5-(trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 1-(4-isopropoxyphenyl)-5-(4-(trifluoromethyl)pyrid-2-yl)indole-2-carboxylic acid ethyl ester (see step (c)) in accordance with the procedure described in Example 1 (c).

25 200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 9.03 (1H, m), 8.62-8.56 (1H, m), 8.29-8.17 (2H, m), 8.10 (1H, dd, $J=1.4, 8.8$ Hz), 7.46 (1H, s), 7.32-7.23 (2H, m), 7.12 (1H, d, $J=8.8$ Hz), 7.07-6.99 (2H, m), 4.69 (1H, septet, $J=6.2$ Hz), 1.32 (6H, d, $J=6.2$ Hz).

Example 91-(4-Isopropoxypyphenyl)-5-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid5 (a) 5-(6-Isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(b), using 5-bromo-2-isopropoxypyridine instead of 2-bromo-5-(trifluoromethyl)pyridine.

10 (b) 1-(4-Isopropoxypyphenyl)-5-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester

A mixture of CuI (7.14 mg, 51 nmol), *N,N*-dimethyl-1,2-diaminoethane (16.7 μ L, 0.153 mmol) and toluene (0.5 mL) was added to a mixture of 5-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester (165 mg, 0.510 mmol; see step (a)), 1-bromo-4-isopropoxybenzene (219 mg, 1.02 mmol), K_3PO_4 (108 mg, 0.510 mmol) and toluene (2 mL) under argon. The mixture was heated at 110°C for 5 h and at 140°C for 16 h, then allowed to cool to room temperature and filtered through Celite®. The filter cake was washed with EtOAc and the combined filtrates were concentrated and purified by chromatography to give the sub-title compound (163 mg, 70%).

20 (c) 1-(4-Isopropoxypyphenyl)-5-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 1-(4-isopropoxypyphenyl)-5-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester (see step (b)) in accordance with the procedure described in Example 1(c).

200 MHz 1H -NMR (DMSO-d₆, ppm) δ 8.43 (1H, d, J=2.2 Hz), 8.00-7.92 (2H, m), 7.54-7.46 (1H, m), 7.32-7.20 (3H, m), 7.06-6.98 (3H, m), 6.84-6.77 (1H, m), 5.27 (1H, septet, J=6.2 Hz), 4.67 (1H, septet, J=6.2 Hz), 1.32 (6H, d, J=6.2 Hz), 1.30 (6H, d, J=6.2 Hz).

Example 101-(4-Methoxyphenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

5 The title compound was prepared from 5-(4-(trifluoromethoxy)-phenyl)indole-2-carboxylic acid ethyl ester (prepared in accordance with Example 1(a) from 5-bromoindole-2-carboxylic acid ethyl ester and 4-(trifluoromethoxy)phenylboronic acid) and 1-bromo-4-methoxybenzene in accordance with the procedure described in Example 9(b), followed by
10 hydrolysis in accordance with the procedure described in Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.8 (1H, br s), 8.03 (1H, d, J =1.7 Hz), 7.83-7.73 (2H, m), 7.57 (1H, dd, J =8.8, 1.7 Hz), 7.48-7.38 (2H, m), 7.41 (1H, s), 7.34-7.25 (2H, m), 7.11-7.03 (3H, m), 3.83 (3H, s).

15 Example 11

1-(4-Ethoxyphenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 10 using 1-bromo-4-ethoxybenzene instead of 1-bromo-4-methoxybenzene.

20 200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.8 (1H, br s), 8.03 (1H, d, J =1.8 Hz), 7.83-7.73 (2H, m), 7.57 (1H, dd, J =8.9, 1.8 Hz), 7.48-7.38 (2H, m), 7.41 (1H, s), 7.32-7.23 (2H, m), 7.10-7.02 (2H, m), 7.04 (1H, d, J =8.9 Hz), 4.10 (2H, q, J =7.0 Hz), 1.37 (3H, t, J =7.0 Hz).

25 Example 12

1-(4-Isopropoxyphenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 10 using 1-bromo-4-isopropoxybenzene instead of 1-bromo-4-methoxybenzene.

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.8 (1H, br s), 8.02 (1H, d, J=1.8 Hz), 7.83-7.73 (2H, m), 7.56 (1H, dd, J=8.9, 1.8 Hz), 7.48-7.38 (2H, m), 7.39 (1H, s), 7.30-7.21 (2H, m), 7.08 (1H, d, J=8.9 Hz), 7.06-6.98 (2H, m), 4.68 (1H, septet, J=6.0 Hz), 1.32 (6H, t, J=6.0 Hz).

5

Example 13

1-(4-Isobutoxyphenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

10 (a) 1-Bromo-4-isobutoxybenzene

4-bromophenol (2.4 g, 13.8 mmol), 1-iodo-2-methylpropane (3.45 mL, 20 mmol), sodium hydroxide (0.8 g, 20 mmol) and DMF (2 mL) were allowed to react to yield the sub-title compound (615 mg, 19%).

15 (b) 1-(4-Isobutoxyphenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 10 using 1-bromo-4-isobutoxybenzene instead of 1-bromo-4-methoxybenzene.

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.8 (1H, br s), 8.03 (1H, d, J=1.7 Hz), 7.83-7.74 (2H, m), 7.57 (1H, dd, J=8.8, 1.7 Hz), 7.47-7.39 (2H, m), 7.41 (1H, s), 7.31-7.23 (2H, m), 7.11-7.03 (2H, m), 7.05 (1H, d, J=8.8 Hz), 3.82 (2H, d, J=6.4 Hz), 2.16-1.95 (1H, m), 1.01 (6H, d, J=6.8 Hz).

Example 141-(4-Cyclobutylmethoxy)phenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid5 (a) 1-Bromo-4-(cyclobutylmethoxy)benzene

4-Bromophenol (2.5 g, 14.5 mmol), (bromomethyl)cyclobutane (1.6 mL, 15 mmol), sodium hydroxide (0.8 g, 20 mmol) and DMF (3 mL) were allowed to react to yield the sub-title compound (1.3 g, 36%).

10 (b) 1-(4-Cyclobutylmethoxy)phenyl)-5-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 10 using 1-bromo-4-(cyclobutylmethoxy)benzene instead of 1-bromo-4-methoxybenzene.

15 200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.8 (1H, br s), 8.03 (1H, d, $J=1.8$ Hz), 7.83-7.74 (2H, m), 7.57 (1H, dd, $J=8.8, 1.8$ Hz), 7.48-7.39 (2H, m), 7.41 (1H, s), 7.32-7.23 (2H, m), 7.11-7.02 (2H, m), 7.05 (1H, d, $J=8.8$ Hz), 4.02 (2H, d, $J=6.7$ Hz), 2.85-2.67 (1H, m), 2.17-1.76 (6H, m)...

20 Example 155-(4-Isopropoxypyhenyl)-1-phenylindole-2-carboxylic acid

The title compound was prepared in accordance with Example 10 using 5-(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester and iodobenzene.

25 200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.9-12.8 (1H, br s), 7.83 (1H, s), 7.61-7.44 (6H, m), 7.43-7.32 (3H, m), 7.10-6.92 (3H, m), 4.63 (1H, septet, $J=6.0$ Hz), 1.27 (6H, d, $J=6.0$ Hz).

Example 161-(5-(Ethoxymethyl)pyrid-2-yl)-5-(4-isopropoxypyhenyl)indole-2-carboxylic acid

5 The title compound was prepared in accordance with Example 10 using 5-(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester and 2-chloro-5-(ethoxymethyl)pyridine.

10 200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 13.0 (1H, br s), 8.52 (1H, s), 7.98-7.87 (2H, m), 7.62-7.44 (4H, m), 7.39-7.29 (2H, m), 7.02-6.92 (2H, m), 4.63 (1H, septet, J=6.1 Hz), 4.57 (2H, s), 3.56 (2H, q, J=7.0 Hz), 1.26 (6H, d, J=6.1 Hz), 1.18 (3H, t, J=7.0 Hz).

Example 175-(4-Isopropoxypyhenyl)-1-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid

15 The title compound was prepared in accordance with Example 10 using 5-(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester and 5-bromo-2-isopropoxypyridine.

20 200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 12.9 (1H, br s), 8.18 (1H, d, J=2.8 Hz), 7.94 (1H, s), 7.74 (1H, dd, J=8.8, 2.8 Hz), 7.61-7.49 (3H, m), 7.45 (1H, s), 7.08 (1H, d, J=8.8 Hz), 7.03-6.93 (2H, m), 6.88 (1H, d, J=8.8 Hz), 5.30 (1H, septet, J=6.2 Hz), 4.64 (1H, septet, J=6.0 Hz), 1.35 (6H, d, J=6.2 Hz), 1.27 (6H, dt, J=6.0 Hz).

Example 1825 5-(4-Isopropoxypyhenyl)-1-(2-naphthyl)indole-2-carboxylic acid(a) 5-(4-Isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester

30 The sub-title compound was prepared in accordance with Example 1(a) from 5-bromoindole-2-carboxylic acid ethyl ester and 4-isopropoxypyhenylboronic acid.

(b) 5-(4-Isopropoxypyhenyl)-1-(2-naphthyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester (see step (a) above) and 2-naphthylboronic acid followed by hydrolysis in accordance with the procedure described in Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.9-12.8 (1H, br s), 8.07-7.96 (5H, m), 7.62-7.45 (7H, m), 7.12 (1H, d, J = 8.8 Hz), 7.01-6.95 (2H, m), 4.62 (1H, septet, J = 6.0 Hz), 1.26 (6H, d, J = 6.0 Hz).

10

Example 19Sodium 5-(4-isopropoxypyhenyl)-1-(2-naphthyl)indole-2-carboxylate

5-(4-Isopropoxypyhenyl)-1-(2-naphthyl)indole-2-carboxylic acid (40 mg, 0.095 mmol; see Example 18) was dissolved in dry THF (1 mL) and

15 NaOMe (3.37 M, 28 μL) was added *via* syringe. After stirring for 30 min at room temperature, the solvents were removed under reduced pressure and the residue dried *in vacuo* to yield the title compound (42 mg, 99%).

Example 205-(4-*tert*-Butylphenyl)-1-(4-(trifluoromethoxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 4-(trifluoromethoxy)phenylboronic acid, followed by hydrolysis in accordance with the procedure described in Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.92 (1H, s), 7.99 (1H, d, J = 1.1 Hz), 7.60-7.53 (7H, m), 7.47-7.43 (3H, m), 7.09 (1H, d, J = 8.8 Hz), 1.29 (9H, s).

30

Example 215-(4-*tert*-Butylphenyl)-1-(4-(methylsulfonyl)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) using 5-
5 (4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 4-
(methylsulfonyl)phenylboronic acid, followed by hydrolysis in accordance
with the procedure described in Example 1(c).

200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 13.03 (1H, s), 8.12-8.05 (2H, m),
8.02 (1H, d, J=1.2 Hz), 7.74-7.67 (2H, m), 7.62-7.57 (3H, m), 7.51-7.44
10 (3H, m), 7.18 (1H, d, J=8.8 Hz), 3.34 (3H, s), 1.30 (9H, s).

Example 225-(4-*tert*-Butylphenyl)-1-(4-methyl-3-nitrophenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-
15 (4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 4-bromo-1-
methyl-2-nitrobenzene.

200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 13.02 (1H, br s), 8.08 (1H, d, J=1.8
Hz), 8.03-8.02 (1H, m), 7.73 (1H, dd, J=8.2, 1.8 Hz), 7.69 (1H, s), 7.65-
7.58 (3H, m), 7.50-7.45 (3H, m), 7.18 (1H, d, J= 8.8 Hz), 2.62 (3H, s), 1.31
20 (9H, s).

Example 235-(4-*tert*-Butylphenyl)-1-(4-(trifluoromethyl)phenyl)indole-2-carboxylic acid

25 The title compound was prepared in accordance with Example 8(c) using 5-
(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 4-
(trifluoromethyl)phenylboronic acid, followed by hydrolysis in accordance
with the procedure described in Example 1(c).

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.99 (1H, s), 8.02-8.01 (1H, m), 7.93-7.89 (2H, m), 7.68-7.56 (5H, m), 7.49-7.44 (3H, m), 7.16 (1H, d, J=8.8 Hz), 1.30 (9H, s).

5 Example 24

5-(4-*tert*-Butylphenyl)-1-(6-isopropoxy-2-naphthyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 2-bromo-6-isopropoxynaphthalene.

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 13.2-12.4 (1H, br s), 8.00 (1H, d, J=1.4 Hz), 7.93-7.87 (3H, m), 7.61-7.51 (3H, m), 7.47-7.37 (5H, m), 7.20 (1H, dd, J=9.0, 2.4 Hz), 7.11 (1H, d, J=8.8 Hz), 4.81 (1H, septet, J=6.1 Hz), 1.35 (6H, d, J=6.1 Hz), 1.29 (9H, s).

15

Example 25

Sodium 5-(4-*tert*-butylphenyl)-1-(4-nitrophenyl)indole-2-carboxylate

5-(4-*tert*-Butylphenyl)-1-(4-nitrophenyl)indole-2-carboxylic acid ethyl ester was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 1-bromo-4-nitrobenzene. This ester (207 mg, 0.47 mmol) was dissolved in dioxane (2 mL) to which aqueous NaOH (1M, 1 mL) was added. The mixture was heated using microwave irradiation at 120°C for 15 min and allowed to cool. The precipitate was filtered off, washed with water and recrystallised from EtOH/EtOAc to yield the title compound.

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 8.34-8.26 (2H, m), 7.85-7.84 (1H, m), 7.62-7.56 (4H, m), 7.45-7.39 (3H, m), 7.20 (1H, d, J= 8.6 Hz), 6.95 (1H, s), 1.30 (9H, s).

Example 26Sodium 5-(4-*tert*-butylphenyl)-1-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)indole-2-carboxylate5 (a) 1-(4-Bromophenylsulfonyl)-4-methylpiperazine

4-Bromobenzene-1-sulfonyl chloride (2.56 g, 10 mmol) in anhydrous CH_2Cl_2 (10 mL) was added to a mixture of 1-methylpiperazine (2.0 g, 20 mmol), pyridine (2.37 g, 30 mmol) and anhydrous CH_2Cl_2 (10 mL) at 0°C. The mixture was stirred at room temperature for 16 h, concentrated, recrystallised, and dried over P_2O_5 to yield the sub-title compound (2.27 g, 71%).

10 (b) Sodium 5-(4-*tert*-butylphenyl)-1-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)indole-2-carboxylate

15 5-(4-*tert*-Butylphenyl)-1-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)indole-2-carboxylic acid ethyl ester was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 1-(4-bromophenylsulfonyl)-4-methylpiperazine (see step (a)). The title compound was prepared by hydrolysis and precipitation in accordance with 20 the procedure described in Example 25.

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 7.86 (1H, d, $J=1.1$ Hz), 7.83-7.77 (2H, m), 7.61-7.56 (4H, m), 7.48-7.40 (3H, m), 7.17 (1H, d, $J=8.8$ Hz), 6.96 (1H, s), 2.99-2.95 (4H, m), 2.42-2.38 (4H, m), 2.16 (3H, s), 1.32 (9H, s).

25 Example 275-(4-*tert*-Butylphenyl)-1-(4-(2-carboxyvinyl)phenyl)indole-2-carboxylic acida) (E)-3-(4-Bromophenyl)acrylic acid ethyl ester

30 $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$ (6.2 g, 17.8 mmol) was added to 4-bromobenzaldehyde (3.0 g, 16.2 mmol) in anhydrous DMF (20 mL) at room temperature. The

mixture was stirred for 2 h, washed with water and extracted with EtOAc. The combined extracts were washed with brine, dried over Na₂SO₄, concentrated and purified by chromatography and distillation to give the sub-title compound (2.99 g, 72%).

5

(b) 5-(4-*tert*-Butylphenyl)-1-(4-(2-carboxyvinyl)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and (E)-3-(4-bromophenyl)acrylic acid ethyl ester.

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 7.98-7.97 (1H, m), 7.86-7.80 (2H, m), 7.69 (1H, d, J=16.0 Hz), 7.63-7.52 (3H, m), 7.50-7.40 (4H, m), 7.35 (1H, s), 7.16 (1H, d, J=8.8 Hz), 6.64 (1H, d, J=16.0 Hz), 1.32 (9H, s).

10

15 Example 28

5-(4-*tert*-Butylphenyl)-1-(4-(2-carboxypropan-2-yloxy)phenyl)indole-2-carboxylic acid

(a) 2-(4-Bromophenoxy)-2-methylpropanoic acid

20 Finely crushed NaOH pellets (23.0 g, 576 mmol) were added in portions to 4-bromophenol (10.4 g, 60 mmol) in acetone (146 mL, 1980 mmol) keeping the temperature below 28°C. CHCl₃ (13 mL, 161 mmol) was added dropwise keeping the temperature below 35°C and the mixture was stirred at that temperature for 30 min, then at reflux for 3 h and at room temperature for 18 h. The mixture was then concentrated and the residue was diluted with water, cooled in an ice-bath and acidified with HCl (6M). The precipitate was allowed to settle and was collected by decantation. Water was added to the solid and the mixture was stirred vigorously for 5 min and then filtered. The solid was dried to give the sub-title compound 30 (14.0 g, 91%).

(b) 2-(4-Bromophenoxy)-2-methylpropanoyl chloride

A mixture of 2-(4-bromophenoxy)-2-methylpropanoic acid (10.0 g, 38.6 mmol), DMF (0.5 mL) and SOCl_2 (40 mL) was heated for 3 h, allowed to cool and distilled to yield the sub-title compound (8.4 g, 78%).

(c) 2-(4-Bromophenoxy)-2-methylpropanoic acid methyl ester

2-(4-Bromophenoxy)-2-methylpropanoyl chloride (2.34 g, 8.4 mmol) in THF (10 mL) was added dropwise whilst stirring to anhydrous MeOH (1.34 g, 42 mmol), Et_3N (1.7 g, 16.8 mmol) and THF at 0 °C. The mixture was stirred at room temperature for 3 h, concentrated and distilled to afford the sub-title compound (1.74 g, 97%).

(d) 5-(4-*tert*-Butylphenyl)-1-(4-(2-carboxypropan-2-yloxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 2-(4-bromophenoxy)-2-methylpropanoic acid methyl ester.

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 7.89-7.88 (1H, m), 7.60-7.55 (2H, m), 7.46-7.41 (3H, m), 7.17-7.13 (3H, m), 7.02 (1H, d, $J=8.6$ Hz), 6.93-6.87 (2H, m), 1.52 (6H, s), 1.31 (9H, s).

Example 295-(4-*tert*-Butylphenyl)-1-(4-(2-methyl-1-(pyrrolidin-1-yl)propan-2-yloxy)-phenyl)indole-2-carboxylic acid(a) 2-(4-Bromophenoxy)-2-methyl-1-(pyrrolidin-1-yl)propan-1-one

Pyrrolidine (1.54 g, 21.6 mmol) in anhydrous MeCN (10 mL) was added with stirring to 2-(4-bromophenoxy)-2-methylpropanoyl chloride (2 g, 7.2 mmol) in anhydrous MeCN (10 mL) at 0°C. The mixture was stirred at

room temperature for 18 h and acidified with HCl (aq. 1M, 40 mL). Brine was added and the mixture was extracted with CH_2Cl_2 . The combined extracts were washed with NaHCO_3 (aq. sat) and brine, dried (Na_2SO_4), and concentrated to give the sub-title compound (2.12 g, 94%).

5

(b) 1-(2-(4-Bromophenoxy)-2-methylpropyl)pyrrolidine

$\text{BH}_3 \times \text{THF}$ (1M, 27.0 minol, 27.0 mL) was added dropwise under argon to 2-(4-bromophenoxy)-2-methyl-1-(pyrrolidin-1-yl)propan-1-one (2.12 g, 6.8 mmol; see step (a)) in THF (40 mL) at 0 °C. The reaction was quenched by careful addition of NH_4Cl (aq. sat.). The reaction mixture was acidified by HCl (1M). NaOH (aq. 0.5M, 30 mL) was added to the filtrate which was then extracted with CH_2Cl_2 . The combined extracts were washed with brine, dried (Na_2SO_4), concentrated and distilled under reduced pressure to yield the title compound (1.5 g, 76%).

15

(c) 5-(4-*tert*-Butylphenyl)-1-(4-(2-methyl-1-(pyrrolidin-1-yl)propan-2-yl-oxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 1-(2-(4-bromophenoxy)-2-methylpropyl)pyrrolidine.

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 7.97-7.96 (1H, m), 7.62-7.44 (5H, m), 7.35 (1H, s), 7.29-7.24 (2H, m), 7.14-7.06 (3H, m), 2.81 (2H, s), 2.79-2.74 (4H, m), 1.80-1.68 (4H, m), 1.33 (6H, s), 1.32 (9H, s).

25

Example 305-(4-*tert*-Butylphenyl)-1-(4-(2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)oxy)phenyl)indole-2-carboxylic acid hydrochloride

5 (a) 1-(2-(4-Bromophenoxy)-2-methylpropanoyl)-4-methylpiperazine hydrochloride

1-(2-(4-Bromophenoxy)-2-methylpropanoyl)-4-methylpiperazine was prepared in accordance to the procedure described in Example 29(a) from 2-(4-bromophenoxy)-2-methylpropanoyl chloride and 1-methylpiperazine (5.3 mL, 17.5 mmol). This compound (2.37 g, 6.95 mmol) was dissolved in Et₂O and HCl in dioxane (4M, 2.26 mL) was added dropwise with stirring. The precipitate was filtered off and dried to yield the sub-title compound (2.5 g, 95%).

15 (b) 5-(4-*tert*-Butylphenyl)-1-(4-(2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)oxy)phenyl)indole-2-carboxylic acid hydrochloride

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 1-(2-(4-bromophenoxy)-2-methylpropanoyl)-4-methylpiperazine hydrochloride (see 20 (a)), followed by precipitation of the hydrochloride salt using HCl (4 M in dioxane).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.76 (1H, s), 11.06 (1H, s), 7.97 (1H, d, J=1.1 Hz), 7.60-7.53 (3H, m), 7.48-7.41 (3H, m), 7.36-7.30 (2H, m), 7.08 (1H, d, J=8.8 Hz), 6.98-6.91 (2H, m), 4.80-4.46 (2H, m), 3.62-2.97 (25 4H, m, overlapped with water peak), 2.82-2.57 (1H, m), 2.68 (3H, s), 2.41-2.13 (1H, m), 1.64 (6H, s), 1.30 (9H, s).

Example 315-(4-*tert*-Butylphenyl)-1-(4-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-indole-2-carboxylic acid5 (a) 2-(4-Bromophenoxy)-2-methylpropan-1-ol

The sub-title compound was prepared by reduction of 2-(4-bromophenoxy)-2-methylpropanoic acid (2 g, 7.7 mmol) with $\text{BH}_3 \times \text{THF}$ (1M, 27.0 mmol, 27.0 mL) in accordance with the procedure described in Example 29(b). Distillation under reduced pressure gave the sub-title compound (1.60 g, 10 85%).

(b) 5-(4-*tert*-Butylphenyl)-1-(4-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1 using 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester and 2-(4-bromophenoxy)-2-methylpropan-1-ol.

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 12.80 (1H, s), 7.99 (1H, d, $J=1.1$ Hz), 7.62-7.55 (3H, m), 7.50-7.42 (3H, m), 7.32-7.25 (2H, m), 7.19-7.12 (2H, m), 7.08 (1H, d, $J=8.8$ Hz), 4.98 (1H, t, $J=5.7$ Hz), 3.45 (2H, d, $J=5.7$ Hz), 1.32 (9H, s), 1.28 (6H, s).

Example 325-(4-Cyclohexylphenyl)-1-(4-isopropoxypyhenyl)indole-2-carboxylic acid25 (a) 5-Bromo-1-(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(c) from 5-bromoindole-2-carboxylic acid ethyl ester and 4-isopropoxypyhenylboronic acid.

(b) 5-(4-Cyclohexylphenyl)-1-(4-isopropoxyphe nyl)indole-2-carboxylic acid ethyl ester

A mixture of 5-bromo-1-(4-isopropoxyphe nyl)indole-2-carboxylic acid ethyl ester (154 mg, 0.38 mmol), K₃PO₄ (282 mg, 1.83 mmol), Pd(OAc)₂ (4.5 mg, 0.02 mmol), tri(*o*-tolyl)phosphine (12 mg, 0.04 mmol), and toluene (3.5 mL) was stirred under argon for 25 min at room temperature. 4-Cyclohexylphenylboronic acid (117 mg, 0.57 mmol) in EtOH (0.5 mL) was added and the mixture was heated at reflux for 1 h. The mixture was allowed to cool, poured into NaHCO₃ (aq. sat.), and extracted with EtOAc. The combined extracts were washed with brine, dried over Na₂SO₄, concentrated and purified by chromatography to give the sub-title compound (170 mg, 93%).

(c) 5-(4-Cyclohexylphenyl)-1-(4-isopropoxyphe nyl)indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 5-(4-cyclohexylphenyl)-1-(4-isopropoxyphe nyl)indole-2-carboxylic acid ethyl ester in accordance with the procedure described in Example 1(c).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.8 (1H, br s), 7.97 (1H, d, J=1.2 Hz), 7.61-7.49 (3H, m), 7.41 (1H, s), 7.33-7.22 (4H, m), 7.10-6.99 (3H, m), 4.69 (1H, septet, J=6.0 Hz), 2.66-2.43 (1H, m, overlapped with DMSO signal), 1.89-1.65 (5H, m), 1.53-1.25 (5H, m) 1.33 (6H, d, J=6.0 Hz).

Example 333-Chloro-5-(4-isopropoxypyhenyl)-1-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid

5 (a) 3-Chloro-5-(4-isopropoxypyhenyl)-1-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester

N-Chlorosuccinimide (37 mg, 280 nmol) and 5-(4-isopropoxypyhenyl)-1-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid ethyl ester (117 mg, 255 nmol; see Example 17) were mixed in CCl₄ (2 mL) and stirred at 80°C for 2 10 h. The mixture was diluted with EtOAc and washed with Na₂S₂O₃ (aq., 10%) and NaHCO₃ (aq., sat.). The combined extracts were washed with water, brine and dried over Na₂SO₄. Concentration gave the sub-title compound (116 mg, 92%).

15 (b) 3-Chloro-5-(4-isopropoxypyhenyl)-1-(6-isopropoxypyrid-3-yl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1(c).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.5-13.3 (1H, br s), 8.20 (1H, d, J=2.7 Hz), 7.79 (1H, s), 7.77 (1H, dd, J=6.0, 2.7 Hz), 7.64-7.56 (3H, m), 20 7.11 (1H, d, J=8.8 Hz), 7.04-6.94 (2H, m), 6.88 (1H, d, J=8.8 Hz), 5.23 (1H, septet, J=6.2 Hz), 4.64 (1H, septet, J=6.0 Hz), 1.27 (6H, d, J=6.2 Hz); 1.25 (6H, d, J=6.0 Hz).

Example 34

25 3-Bromo-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid

(a) 3-Bromo-1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester

N-Bromosuccinimide (467 mg, 2.62 mmol) was added in portions to 1,5-bis(4-isopropoxypyhenyl)indole-2-carboxylic acid ethyl ester (1.0 g, 2.19

mmol; see Example 3) in CCl_4 (50 mL) at room temperature. The mixture was stirred at 60°C for 2.5 h after which additional *N*-bromosuccinimide (100 mg, 560 μmol) was added and the mixture was heated for another 1 h. The mixture was allowed to cool, poured into $\text{Na}_2\text{S}_2\text{O}_3$ (aq., 10%) and extracted with EtOAc. The combined extracts were washed with $\text{Na}_2\text{S}_2\text{O}_3$ (aq., 10%), NaHCO_3 (aq., sat.) and brine and then dried over Na_2SO_4 . Concentration and purification by chromatography gave the sub-title compound (968 mg, 82%).

10 (b) 3-Bromo-1,5-bis(4-isopropoxypyphenyl)indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 13.5-13.2 (1H, br s), 7.72 (1H, d, J =1.2 Hz), 7.64-7.57 (3H, m), 7.35-7.26 (2H, m), 7.10 (1H, d, J =8.8 Hz), 7.08-6.98 (4H, m), 4.69 (1H, septet, J =6.0 Hz), 4.66 (1H, septet, J =6.0 Hz),
15 1.33 (6H, d, J =6.0 Hz), 1.29 (6H, d, J =6.0 Hz).

Example 35

3-Chloro-1-(4-isopropoxypyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

20

Method 1

(a) 5-Bromo-3-chloro-1H-indole-2-carboxylic acid ethyl ester

A mixture of 5-bromoindole-2-carboxylic acid ethyl ester (4.00 g, 14.9 mmol), sulfonylchloride (1.8 mL, 22.4 mmol) and benzene (125 mL) was stirred at 90°C for 2.5 h. The mixture was cooled to room temperature, NaHCO_3 (aq., sat.) was added and the mixture extracted with EtOAc. The combined extracts were washed with water, brine and dried over Na_2SO_4 . Concentration and recrystallisation (from toluene) gave the sub-title compound (3.87 g 85 %).

(b) 5-Bromo-3-chloro-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(c), using 5-bromo-3-chloro-1H-indole-2-carboxylic acid ethyl ester (see step

5 (a) above) and 4-isopropoxypyhenylboronic acid.

(c) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(a),

10 using 5-bromo-3-chloro-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (b)) and bis(pinacolato)diboron.

(d) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

15 The sub-title compound was prepared in accordance with Example 8(b), from 3-chloro-1-(4-isopropoxypyhenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (c)) and 2-bromo-5-(trifluoromethyl)pyridine.

20 (e) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 3-chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester in accordance with the procedure described in Example 1(c).

25 200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 9.06-9.00 (1H, m) 8.48-8.42 (1H, m) 8.32-8.21 (2H, m) 8.17-8.05 (1H, m) 7.37-7.27 (2H, m) 7.19 (1H, d, J=8.8 Hz) 7.10-6.98 (2H, m) 4.67 (1H, septet, J=5.9 Hz) 1.31 (6H, d, J=5.9 Hz).

Method 2(a) 3-Chloro-5-iodo-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester

A mixture of 5-bromo-3-chloro-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (2.80 g, 6.44 mmol) (prepared in accordance with the procedure described in Example 35, Method 1, step (b)), CuI (122 mg, 0.64 mmol), NaI (1.94 g, 12.9 mmol), *N,N*-dimethyl-1,2-diaminoethane (142 μ L, 1.28 mmol) and 1,4-dioxane (10 ml) was stirred at 120°C for 24 h. The mixture was cooled to room temperature and diluted with EtOAc (200 ml). The combined organic phase was washed with diluted NH₄OH solution (2 x 200 mL), HCl (0.1 N solution; 2 x 200mL), brine (100 mL) and dried over Na₂SO₄. Filtration and concentration of the organic phase gave the sub-title compound (3.02 g 97 %).

15 (b) 3-Chloro-5-(dihydroxyboryl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester

To solution of 3-chloro-5-iodo-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (1.45 g, 3.0 mmol, see step (a) above) in THF (9 mL) was added *i*-PrMgCl x LiCl (0.95 M solution in THF; 3.26 mL, 3.1 mmol) at -40°C over 5 min. After stirring for 15 min at -40°C, B(OEt)₃ (1.56 mL, 9.0 mmol) was added. The temperature of the reaction mixture was allowed to reach 0°C over 2 h, then HCl (2.5 M solution in water; 3.6 mL, 36 mmol) was added and stirring continued for a further 1 h at 0°C. The reaction mixture was diluted with brine (70 mL) and extracted with *t*-BuOMe (4x70 mL). The combined organic extracts were washed with brine (100mL), dried over Na₂SO₄ and concentrated. The solid thereby obtained was washed several times with light petrol and filtered affording pure sub-title compound (1.04 g, 86 %)

(c) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

A stirred mixture of 3-chloro-5-(dihydroxyboryl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (200 mg, 0.50 mmol; see step (b) above), 2-bromo-5-(trifluoromethyl)pyridine (170 mg, 0.75 mmol), sodium carbonate (2M in water, 0.75 mL, 1.5 mmol), Pd(PPh₃)₄ (29 mg, 0.025 mmol), EtOH (0.4 mL) and toluene (1.6 mL) was heated at 85°C for 3 h. The reaction was diluted with EtOAc, washed with brine, dried over MgSO₄, concentrated and purified by chromatography to give the sub-title compound (239 mg, 95%).

(d) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 3-chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester in accordance with the procedure described in Example 1(c).

Method 3

(a) 3-Chloro-1-(4-isopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

t-BuLi (3.25 mL of 1.5M solution in pentane) was added dropwise at -78°C to Et₂O (5 mL). To the resulting solution was added, *via* syringe, a solution of 2-bromo-5-(trifluoromethyl)pyridine (550 mg, 2.43 mmol) in Et₂O (2.5 mL). Stirring at -78°C was continued for 20 min after which the cold reaction mixture was transferred *via* cannula to a cooled (-78°C) 1M solution of ZnCl₂ in Et₂O (5.25 mL, 5.35 mmol). The reaction was allowed to warm to room temperature and left to stir for 3 h. THF (10 mL) was then added and the resulting solution was transferred *via* cannula to a mixture of 5-bromo-3-chloro-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (see Example 35, Method 1, step (b)) (531 mg, 1.22 mmol),

Pd(dppf)Cl₂ (118.4 mg, 0.145 mmol), CuI (56.2 mg, 0.295 mmol) and *N*-methylpyrrolidin-2-one (2.5 mL) under argon. The reaction was heated at 80°C for 6 h, poured into NH₄Cl (aq. sat., 50 mL) and extracted with *t*-BuOMe (3x25 mL). The combined organic extracts were washed with 5 brine, dried (Na₂SO₄), then filtered through a Celite® pad and the filter cake was washed with *t*-BuOMe. The solvent was removed and the residue dissolved in dry Et₂O and HCl (4M in dioxane; 360 µL, 1.4 mmol) was added. After stirring for 10 min, solvents were removed by evaporation and the residue was twice recrystallised from EtOH to yield the sub-title 10 compound (462 mg, 75%).

(b) 3-Chloro-1-(4-isopropoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

15 To a solution of 3-chloro-1-(4-isopropoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above; 500 mg, 1.0 mmol) in dioxane (5 mL) was added NaOH (aq. 2N, 2.5 mL) and the reaction was refluxed for 4 h. After cooling to room temperature, the reaction was diluted with water and acidified by the addition of HCl (aq. 20 1N) to about pH 6. The precipitate was filtered, washed with water and dried. Recrystallisation (from EtOAc/petroleum ether) afforded the title compound (289 mg, 62%).

Example 363-Chloro-1-(6-cyclopentoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid5 (a) 3-Chloro-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

N-Chlorosuccinimide (480 mg, 3.86 mmol) and 5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (800 mg, 2.4 mmol; see Example 8 (b)) were mixed in CCl_4 (50 mL) and stirred at 80°C for 2 h. The mixture was diluted with EtOAc and washed with $\text{Na}_2\text{S}_2\text{O}_3$ (aq., sat.), NaHCO_3 (aq., sat.), brine and dried over Na_2SO_4 . Concentration gave the sub-title compound (870 mg, 98%).

15 (b) 5-Bromo-2-cyclopentoxypyridine

15 A mixture of 5-bromo-1H-pyridin-2-one (4.0 g, 23 mmol), Ag_2CO_3 (3.77 g, 1.37 mmol), cyclopentyl bromide (7.4 mL, 29 mmol) and toluene (30 ml) was stirred at 60°C for 2 days. The reaction was filtered through Celite® and the filter cake was washed with EtOAc. Concentration and vacuum distillation gave the sub-title compound (5.09 g, 92 %).

20

(c) 6-Cyclopentoxypyridine-3-boronic acid

20 To a mixture of 5-bromo-2-cyclopentoxypyridine (2.5 g, 10.3 mmol, see step (b) above), $\text{B}(\text{O}-i\text{Pr})_3$ (2.33 g, 13.4 mmol), THF (4.1 mL) and toluene (16.5 mL) was portion-wise added BuLi (2.5 M in hexane; 4.96 ml, 13.4 mmol) at -70°C over 1 h. The reaction mixture was stirred over a further 40 min at -70°C and then allowed to warm to -20°C. The acidity of the reaction mixture was adjusted to about pH 1 by addition of HCl (2 M aq. solution). The reaction was diluted with water (50 mL) and extracted with Et_2O (2x50 mL). The pH of the water phase was then adjusted to about pH 7 by the addition of NaOH (5 M aq. solution). Brine was added and the

product was extracted with EtOAc (4x50 mL). Removal of the solvent afforded the sub-title compound (0.99 g, 46 %).

(d) 3-Chloro-1-(6-cyclopentoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

5

The sub-title compound was prepared in accordance with Example 8(c), using 3-chloro-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above) and 6-cyclopentoxypyridine-3-boronic acid (see step (c) above).

10

(e) 3-Chloro-1-(6-cyclopentoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 3-chloro-1-(6-cyclopentoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-15 carboxylic acid ethyl ester (see step (d) above) in accordance with the procedure described in Example 1(c).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 9.05 (1H, s) 8.54 (1H, s) 8.36-8.17 (4H, m) 7.82 (1H, dd, J=8.8, 2.7 Hz) 7.22 (1H, d, J=9.0 Hz) 6.92 (1H, d, J=8.8 Hz) 5.85-5.38 (1H, m) 2.08-1.51 (8H, m).

20

Example 37

1-(6-Cyclopentoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 36(d) from 25 5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 8(b)) and 6-cyclopentoxypyridine-3-boronic acid (see Example 36(c)), followed by ester hydrolysis (see Example 36(e)).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 9.00 (1H, s) 8.63-8.58 (1H, m) 8.28-8.18 (3H, m) 8.12 (1H, dd, J=8.8, 1.7 Hz) 7.76 (1H, dd, J=8.8, 2.7 Hz) 7.50

(1H, s) 7.17 (1H, d, J=8.9 Hz) 6.89 (1H, d, J=8.8 Hz) 5.31 (1H, septet, J=6.2 Hz) 1.35 (6H, d, J=6.2 Hz).

Example 38

5 1-(6-Isopropoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

(a) 5-Bromo-2-isopropoxypyridine

The sub-title compound was prepared in accordance with Example 36(b) from isopropylbromide and 5-bromo-1H-pyridin-2-one.

(b) 6-Isopropoxypyridine-3-boronic acid

The sub-title compound was prepared in accordance with Example 36(c) from 5-bromo-2-isopropoxypyridine.

15 (c) 1-(6-Isopropoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(c) from 5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 8(b)) and 6-isopropoxypyridine-3-boronic acid (see step (b) above).

(d) 1-(6-Isopropoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

25 The title compound was prepared by hydrolysis of 1-(6-isopropoxypyrid-3-yl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (c) above) in accordance with the procedure described in Example 1(c).

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 9.05 (1H, s) 8.54 (1H, s) 8.36-8.17 (4H, m) 7.82 (1H, dd, J=8.8, 2.7 Hz) 7.22 (1H, d, J=9.0 Hz) 6.92 (1H, d, J=8.8 Hz) 5.85-5.38 (1H, m) 2.08-1.51 (8H, m).

5 Example 39

5-(4-*tert*-Butylphenyl)-1-(4-cyclopropoxyphe nyl)-1H-indole-2-carboxylic acid

(a) 1-Bromo-4-(2-bromoethoxy)benzene

10 A mixture of 4-bromophenol (30 g, 173 mmol), dibromoethane (40 mL, 464 mmol), NaOH (11.0 g, 275 mmol) and water (430 mL) was refluxed for 11 h. The phases were separated and the organic phase was further purified by distillation, yielding the sub-title compound (40.1 g 83 %).

15 (b) 1-Bromo-4-vinyloxybenzene

To a solution of 1-bromo-4-(2-bromoethoxy)benzene (19.9 g, 100 mmol; see step (a) above) in THF (120 mL) was portion-wise added *t*-BuOK (14.0 g, 125 mmol) over 10 min at 0°C. After stirring at room temperature for 16 h, the mixture was diluted with water (400 mL) and the product was 20 extracted with light petrol (4x100 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄), concentrated and distilled under vacuum to yield the sub-title compound (11.5 g, 58%).

(c) 1-Bromo-4-cyclopropoxyphe nylbenzene

25 To mixture of 1-bromo-4-vinyloxybenzene (11.5 g, 58 mmol), chloroiodomethane (41g, 232 mmol) and dichloroethane (180 mL) was added diethylzinc (15 % solution in hexanes; 95.5 mL, 116 mmol) over 3 h at 0°C. After 30 min stirring, NH₄Cl solution (200 mL, aq. sat.) and light petrol (300 mL) was added. The organic phase was separated and concentrated *in* 30 *vacuo* (8 bar, 50 °C). The residue was redissolved in light petrol and the

insoluble material was filtered off. The filtrate was concentrated to afford sub-title compound (11.7 g, 94%).

5 (d) 5-(4-*tert*-Butylphenyl)-1-(4-cyclopropoxypyhenyl)-1H-indole-2-carboxy-

lic acid ethyl ester

The sub-title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) and 1-bromo-4-cyclopropoxypyhenzene (see step (c) above).

10 (e) 5-(4-*tert*-Butylphenyl)-1-(4-cyclopropoxypyhenyl)-1H-indole-2-carboxy-

lic acid

The sub-title compound was prepared by hydrolysis of 5-(4-*tert*-butylphenyl)-1-(4-cyclopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (c) above) in accordance with the procedure described in Example

15 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 7.96 (1H, d, $J=1.7$) 7.63-7.50 (3H, m) 7.49-7.37 (3H, m) 7.34-7.25 (2H, m) 7.22-7.12 (2H, m) 7.05 (1H, d, $J=8.8$ Hz) 3.97-3.85 (1H, m) 1.30 (9H, s) 0.89-0.66 (4H, m).

20 Example 40

1-(4-Cyclopropoxypyhenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

(a) 4-Cyclopropoxypyhenylboronic acid

25 To a solution of 4-bromo-4-cyclopropoxypyhenzene (5.0 g, 23.4 mmol, see Example 39(c)) in THF (80 mL) at -78°C was added *n*-BuLi (2.5 M solution in hexane; 9.76 mL, 24.4 mmol) over 17 min. After 40 min, $\text{B}(\text{OEt})_3$ (5.9 mL, 34.3 mmol) was added and the reaction was warmed to room temperature and stirred at ambient temperature for 18 h. After re-cooling to 0°C, HCl (1M solution; 70 mL, aq.) was added. After 30 min the mixture

was extracted with *t*-BuOMe (3x50 mL), the combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated. The residue was washed with light petrol and filtered yielding the sub-title compound (1.5 g, 34 %).

5

(b) 1-(4-Cyclopropoxypyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(c) from 5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 8(b)) and 4-cyclopropoxypyphenylboronic acid (see step 10 (a) above).

(c) 1-(4-Cyclopropoxypyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

15 The title compound was prepared by hydrolysis of 1-(4-cyclopropoxypyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (b) above) in accordance with the procedure described in Example 1(c).

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 9.03 (1H, s) 8.47 (1H, s) 8.33-8.19
20 (2H, m) 8.13 (1H, dd, $J=8.8, 1.5$ Hz) 7.42-7.30 (2H, m) 7.23-7.11 (3H, m)
3.97-3.85 (1H, m) 0.90-0.65 (4H, m).

Example 41

3-Chloro-1-(4-cyclopropoxypyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 3-chloro-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 36(a)) and 4-cyclopropoxypyphenylboronic acid (see Example 40(a)), followed by ester hydrolysis in accordance with Example 30 1(c).

200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 9.03 (1H, s) 8.47 (1H, s) 8.33-8.19 (2H, m) 8.13 (1H, dd, J=8.8, 1.5 Hz) 7.42-7.30 (2H, m) 7.23-7.11 (3H, m) 3.97-3.85 (1H, m) 0.90-0.65 (4H, m).

5 Example 42

5-(4-Carbamoylphenyl)-1-(4-cyclopropoxypyphenyl)-1H-indole-2-carboxylic acid

(a) 5-(4-Cyanophenyl)-1H-indole-2-carboxylic acid ethyl ester

10 The sub-title compound was prepared in accordance with Example 8(b) from 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-2-carboxylic acid ethyl ester (see Example 8(a)) and 4-iodobenzonitrile.

(b) 5-(4-Cyanophenyl)-1-(4-cyclopropoxypyphenyl)-1H-indole-2-carboxylic acid ethyl ester

15 The sub-title compound was prepared in accordance with Example 8(c) from 5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above) and 4-cyclopropoxypyphenylboronic acid (see Example 40(a)).

20 (c) 5-(4-Carbamoylphenyl)-1-(4-cyclopropoxypyphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 5-(4-cyanophenyl)-1-(4-cyclopropoxypyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (b) above) in accordance with the procedure described in Example 1(c).

25 200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 12.8 (1H, br s) 8.09 (1H, d, J=1.6) 8.03-7.90 (3H, m) 7.79-7.70 (2H, m) 7.63 (1H, dd, J=8.9, 1.6 Hz) 7.42 (1H, s) 7.38-7.27 (3H, m) 7.23-7.14 (2H, m) 7.08 (1H, d, J=8.9 Hz) 3.97-3.85 (1H, m) 0.89-0.66 (4H, m).

Example 433-Chloro-5-(6-cyclopentoxypyrid-3-yl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(b) from 3-chloro-1-(4-isopropoxypyhenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 35(c)) and 5-bromo-2-cyclopentoxypyridine (see Example 36(b)), followed by ester hydrolysis in accordance with Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 8.48 (1H, d, $J=2.5$ Hz) 8.02 (1H, dd, $J=8.8, 2.5$ Hz) 7.84 (1H, d, $J=1.5$ Hz) 7.61 (1H, dd, $J=8.8, 1.5$ Hz) 7.35-7.24 (2H, m) 7.12 (1H, d, $J=8.8$ Hz) 7.08-6.98 (2H, m) 6.84 (1H, d, $J=8.8$ Hz) 5.46-5.33 (1H, m) 4.68 (1H, septet, $J=5.9$ Hz) 2.06-1.50 (8H, m) 1.32 (6H, d, $J=5.9$ Hz).

15 Example 443-Chloro-1-(4-isopropoxypyhenyl)-5-(5-propylpyrimidin-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 35, Method 1, step (d) from 3-chloro-1-(4-isopropoxypyhenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 35, Method 1, step (c)) and 2-chloro-5-propylpyrimidine, followed by ester hydrolysis in accordance with Example 1(c).

200 MHz ^1H -NMR (DMSO- d_6 , ppm) δ 8.79-8.67 (3H, m) 8.37 (1H, dd, $J=8.8, 1.5$ Hz) 7.38-7.26 (2H, m) 7.17 (1H, d, $J=8.8$ Hz) 7.09-6.98 (2H, m) 4.68 (1H, septet, $J=5.9$ Hz) 2.60 (2H, t, $J=7.7$ Hz) 1.64 (2H, m) 1.32 (6H, d, $J=5.9$ Hz) 0.93 (3H, t, $J=7.7$ Hz).

Example 453-Chloro-5-(4-cyclohexylphenyl)-1-(5-cyclopentylaminopyrid-2-yl)-1H-indole-2-carboxylic acid sodium salt5 (a) 3-Chloro-5-(4-cyclohexylphenyl)-1H-indole-2-carboxylic acid

The sub-title compound was prepared in accordance with Example 1(a) from 5-bromo-3-chloroindole-2-carboxylic acid ethyl ester (see Example 35, Method 1, step (a)) and 4-cyclohexylphenylboronic acid.

10 (b) (6-Bromopyrid-3-yl)cyclopentylamine

To a solution of 6-bromopyrid-3-ylamine (2.0 g, 11.6 mmol) in CH_2Cl_2 (30 mL) was added cyclopentanone (1.3 mL, 15.5 mmol), followed by TiCl_4 (1.4 mL, 12.7 mmol) in CH_2Cl_2 (20 mL) and after stirring for 3.5 h at room temperature, NaBH_3CN (2.17 g, 34.5 mmol) was added portion-wise. The reaction was left to stir overnight at ambient temperature, diluted with *t*-BuOMe (200 mL), washed with water, brine and dried (Na_2SO_4). Solvent removal and purification by chromatography afforded the sub-title compound (880 mg, 40%).

20 (c) 3-Chloro-5-(4-cyclohexylphenyl)-1-(5-cyclopentylaminopyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The title compound was prepared in accordance with Example 1(b) from 3-chloro-5-(4-cyclohexylphenyl)-1H-indole-2-carboxylic acid (see step (a) above) and (6-bromopyrid-3-yl)cyclopentylamine (see step (b) above).

25 (d) 3-Chloro-5-(4-cyclohexylphenyl)-1-(5-cyclopentylaminopyrid-2-yl)-1H-indole-2-carboxylic acid sodium salt

A mixture of 3-chloro-5-(4-cyclohexylphenyl)-1-(5-cyclopentylaminopyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (c) above) (120 mg, 0.22 mmol), NaOH (2M aq., 1.0 mL, 2.0 mmol) and dioxane (2.0 mL)

was heated in a sealed vessel at 140°C for 2 h. After dilution with water (5 mL) the precipitate formed was filtered, washed with water and dried (P₂O₅) to yield the title compound (105 mg, 85%).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 7.83 (1H, d, J=1.6 Hz) 7.63-7.56
5 (3H, m) 7.41 (2H, m) 7.31-7.25 (2H, m) 7.12 (1H, d, J=8.8 Hz) 7.01 (1H, dd, J=8.8, 2.6 Hz) 5.98 (1H, d, J=6.4 Hz) 3.81-3.67 (1H, m) 2.59-2.51 (1H, m) 2.00-1.13 (18H, m).

Example 46

10 3-Chloro-5-(4-cyclohexylphenyl)-1-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid sodium salt

The title compound was prepared in accordance with Example 45 from 3-chloro-5-(4-cyclohexylphenyl)-1H-indole-2-carboxylic acid (Example 45(a)) and 2-bromo-5-(trifluoromethyl)pyridine, followed by ester hydrolysis in
15 accordance with Example 45(d).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 8.97 (1H, s) 8.30 (1H, dd, J=8.6, 2.1 Hz) 7.88 (1H, d, J=8.6 Hz) 7.72-7.71 (1H, m) 7.65-7.52 (4H, m) 7.34-7.28 (2H, m) 2.61-2.46 (1H, m, overlapped with DMSO) 1.83-1.63 (5H, m) 1.53-1.15 (5H, m).

20

Example 47

3-Chloro-5-(5-cyclopentylaminopyrid-2-yl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(b) from 3-chloro-1-(4-isopropoxypyhenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 35, Method 1, step (c)) and 6-bromopyrid-3-ylcyclopentylamine (see Example 45(b)), followed by ester hydrolysis according to Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 8.28-8.20 (1H, m) 8.14-8.04 (1H, m) 7.96 (1H, d, J=1.5 Hz) 7.89-7.80 (1H, m) 7.68-7.56 (1H, m) 7.38-7.25

(2H, m) 7.19 (1H, d, $J=8.7$ Hz) 7.12-6.98 (2H, m) 4.69 (1H, septet, $J=5.9$ Hz) 3.96-3.78 (1H, m) 3.78-3.28 (3H, m) 2.08-1.84 (2H, m) 1.81-1.37 (6H, m) 1.32 (6H, d, $J=5.9$ Hz).

5 Example 48

5-(5-Bromopyrimidin-2-yl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid

(a) 1-Bromo-4-cyclopentoxybenzene

10 A mixture of 4-bromophenol (40 g, 231 mmol), cyclopentylbromide (50 ml, 462 mmol), NaOH (18.5 g, 462 mmol) and DMF (150 mL) was stirred at 100°C for 13.5 h, poured into water (300 mL) and extracted with *t*-BuOMe (4x100 mL). The combined organic extracts were washed with water (2x100 mL), brine, dried (Na_2SO_4), concentrated and distilled *in vacuo* to yield the sub-title compound (46.4 g, 94 %).

(b) 4-Cyclopentoxyphenylboronic acid

The sub-title compound was prepared in accordance with Example 40(a) from 1-bromo-4-cyclopentoxybenzene (see step (a) above).

20 (c) 5-Bromo-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(c), using 5-bromo-1H-indole-2-carboxylic acid ethyl ester and 4-cyclopentoxyphenylboronic acid (see step (b) above).

(d) 1-(4-Cyclopentoxyphenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(a) from 5-bromo-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (c) above) and bis(pinacolato)diboron.

5 (e) 5-Bromo-1H-pyrimidin-2-one

To a solution of 2-amino-5-bromopyrimidine (2.0 g, 11.5 mmol) in acetic acid (35 mL) was added a solution of NaNO₂ (4.76 g, 69 mmol) in water 10 (25 mL) at room temperature over 1.5 h. After stirring at room temperature for 5 h the reaction mixture was partly evaporated, the precipitate formed was filtered and washed with water to yield the sub-title compound (1.4 g, 70 %).

15 (f) 2,5-Dibromopyrimidine

A mixture of 5-bromo-1H-pyrimidin-2-one (see step (e) above; 1.40 g, 8.0 mmol), POBr₃ (2.8 g, 9.8 mmol) and PBr₃ (7.7 mL) was refluxed for 1.5 h. After cooling to room temperature the reaction was poured into a mixture of crushed ice and Na₂CO₃ (saturated aq. solution) and extracted with EtOAc 20 (3x100 mL). The combined organic extracts were washed with brine, dried with Na₂SO₄ and concentrated. The residue was re-dissolved in EtOAc/light petrol (1:1) and filtered through a silica pad. Concentration of the filtrate gave the sub-title compound (0.95 g, 50 %).

25 (g) 5-(5-Bromopyrimidin-2-yl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 8(b), from 1-(4-cyclopentoxyphenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (d) above) and 2,5-dibromopyrimidine (see step (f) above).

(h) 5-(5-Bromopyrimidin-2-yl)-1-(4-cyclopentoxypyphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 5-(5-bromopyrimidin-2-yl)-1-(4-cyclopentoxypyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (g) above) in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.1-12.7 (1H, br.s) 9.02 (2H, s) 8.80 (1H, d, J=1.5 Hz) 8.27 (1H, dd, J=8.9, 1.5 Hz) 7.48 (1H, s) 7.32-7.22 (2H, m) 7.10 (1H, d, J=8.9 Hz) 7.06-6.96 (2H, m) 4.93-4.82 (1H, m) 2.06-1.48 (8H, m).

Example 49

1-(4-Cyclopentoxypyphenyl)-5-(5-pyrid-2-ylpyrimidin-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(b) from 5-(5-bromopyrimidin-2-yl)-1-(4-cyclopentoxypyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see Example 48(g)) and 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.3-12.4 (1H, br.s) 9.27 (2H, s) 9.12-9.04 (1H, m) 8.90 (1H, d, J=1.5 Hz) 8.73-8.62 (1H, m) 8.40 (1H, dd, J=8.8, 1.5 Hz) 8.34-8.24 (1H, m) 7.65-7.50 (2H, m) 7.36-7.24 (2H, m) 7.13 (1H, d, J=8.8 Hz) 7.08-6.97 (2H, m) 4.95-4.82 (1H, m) 1.92-1.47 (8H, m).

Example 503-Chloro-1-(4-cyclopentoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

5 (a) 5-Bromo-3-chloro-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with the procedure described in Example 8(c) using 5-bromo-3-chloro-1H-indole-2-carboxylic acid ethyl ester (see Example 35, Method 1, step(a)) and 4-10 cyclopentoxyphenylboronic acid instead of 4-isopropoxyphenylboronic acid.

(b) 3-Chloro-1-(4-cyclopentoxyphenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester

15 The sub-title compound was prepared from 5-bromo-3-chloro-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above) in accordance with the procedure described in Example 35, Method 1, step (c).

20 (c) 3-Chloro-1-(4-cyclopentoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared from 3-chloro-1-(4-cyclopentoxyphenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see step (b) above) in accordance with the 25 procedure described in Example 8(a).

(d) 3-Chloro-1-(4-cyclopentoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-carboxylic acid

The title compound was prepared by hydrolysis of 3-chloro-1-(4-cyclopentoxyphenyl)-5-(5-trifluoromethylpyrid-2-yl)-1H-indole-2-

carboxylic acid ethyl ester (see step (c) above) in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.8-13.0 (1H, br s) 9.07-9.01 (1H, m) 8.51 (1H, s) 8.35-8.22 (2H, m) 8.18 (1H, dd, J=8.8, 1.2 Hz) 7.37-7.27
5 (2H, m) 7.19 (1H, d, J=8.8 Hz) 7.08-6.99 (2H, m) 4.94-4.83 (1H, m) 2.07-1.87 (2H, m) 1.86-1.54 (6H, m).

Example 51

3-Chloro-1-(4-cyclopentoxphenyl)-5-(6-(piperidin-1-yl)pyridin-3-yl)-1H-
10 indole-2-carboxylic acid

(a) Trifluoromethanesulfonic acid 5-bromopyrid-2-yl ester

To a solution of 5-bromo-1H-pyridin-2-one (4.0 g, 23.0 mmol) in CH₂Cl₂ (100 mL) was added Et₃N (3.9 mL, 27.6 mmol) and the resulting solution
15 was cooled to -45°C, after which trifluoromethanesulfonic acid anhydride (5.8 mL, 34.5 mmol) was gradually added *via* syringe. The reaction was warmed to room temperature and left to stir overnight. The reaction was then washed twice with NaHCO₃ (aq. sat.), brine and dried (Na₂SO₄). Solvent removal and distillation of the residue *in vacuo* afforded the sub-
20 title compound (6.51 g, 93%).

(b) 3-Bromo-6-(piperidin-1-yl)pyridine

A mixture of trifluoromethanesulfonic acid 5-bromopyrid-2-yl ester (see step (a) above; 1.5 g, 4.9 mmol), piperidine (1.07 mL, 10.8 mmol) and DMF
25 (5 mL) was heated at 40°C for 3 h. DMF was then removed *in vacuo*, water (20 mL) was added to the residue and the product extracted with EtOAc (3x15 mL) and CH₂Cl₂ (15 mL). The combined organic extracts were washed with brine and dried (Na₂SO₄). After removal of the solvent, the residue was dissolved in Et₂O and HCl (4M in dioxane; 4 mL) was added.

The precipitate was filtered, washed with Et₂O and dried to afford the sub-title compound (994 mg, 84%).

(c) 3-Chloro-1-(4-cyclopentoxypyphenyl)-5-(6-(piperidin-1-yl)pyridin-3-yl)-

5 1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(b), from 1-(4-cyclopentoxypyphenyl)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester (see Example 50(b)) and 3-bromo-6-(piperidin-1-yl)pyridine (see step (b) above), followed by ester hydrolysis 10 in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.5-13.1 (1H, br s) 8.44 (1H, d, J=2.4 Hz) 7.85 (1H, dd, J=9.0, 2.6 Hz) 7.79 (1H, d, J=1.1 Hz) 7.60 (1H, dd, J=8.8, 1.6 Hz) 7.32-7.24 (2H, m) 7.07 (1H, d, J=8.8 Hz) 7.05-6.98 (2H, m) 15 6.89 (1H, d, J=9.0 Hz) 4.92-4.82 (1H, m) 3.57-3.52 (4H, m) 2.01-1.50 (14H, m).

Example 52

3-Chloro-5-(5-chloropyrid-2-yl)-1-(4-cyclopentoxypyphenyl)-1H-indole-2-

20 carboxylic acid

(a) 5-Iodo-1-(4-cyclopentoxypyphenyl)-3-chloro-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 35, 25 Method 2, step (a) from 5-bromo-1-(4-cyclopentoxypyphenyl)-3-chloro-1H-indole-2-carboxylic acid ethyl ester (see Example 50, step (a)).

(b) 3-Chloro-5-(dihydroxyboryl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester

The sub-title compound was prepared in accordance with Example 35, Method 2, step (b) from 3-chloro-1-(4-cyclopentoxyphenyl)-5-iodo-1H-indole-2-carboxylic acid (see step (a) above).

(c) Trifluoromethanesulfonic acid 5-chloropyrid-2-yl ester

The sub-title compound was prepared in accordance with Example 51(a) from 5-chloro-1H-pyridin-2-one.

10

(d) 3-Chloro-5-(5-chloropyrid-2-yl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester

To a stirred suspension of 3-chloro-5-(dihydroxyboryl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (b) above; 214 mg, 0.5 mmol), trifluoromethanesulfonic acid 5-chloropyrid-2-yl ester (see step (c) above; 130.0 mg, 0.5 mmol) and K_3PO_4 (200 mg, 0.95 mmol) in THF (2.0 mL) under argon at room temperature was added a mixture of $Pd(OAc)_2$ (23.0 mg, 0.1 mmol) and tricyclohexylphosphine (34 mg, 0.12 mmol) in THF (2.0 mL). The reaction was stirred at ambient temperature for 12 h, diluted with Et_2O (10 mL), washed with brine and dried (Na_2SO_4). Concentration and purification by chromatography afforded the sub-title product (100 mg, 40%).

(e) 3-Chloro-5-(5-chloropyrid-2-yl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 35, Method 3, step (b) from 3-chloro-5-(5-chloropyrid-2-yl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (d) above).

200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 8.74-8.72 (1H, m) 8.44 (1H, s) 8.16-8.10 (2H, m) 8.02 (1H, dd, J=8.8, 2.6 Hz) 7.38-7.30 (2H, m) 7.18 (1H, d, J=9.0 Hz) 7.09-7.03 (2H, m) 4.95-4.88 (1H, m) 2.02-1.64 (8H, m).

5 Example 53

5-(4-Chlorophenyl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid

(a) 5-(4-Chlorophenyl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester

10 A mixture of 5-bromo-3-chloro-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (see Example 35(b); 402 mg, 1.0 mmol), K₃PO₄ (716 mg, 3.37 mmol), Pd(OAc)₂ (22 mg, 0.1 mmol) and biphenyl-2-yl-di-*tert*-butylphosphine (53 mg, 0.18 mmol) in toluene (10 mL) was stirred at ambient temperature for 10 min after which 4-chlorophenyl boronic acid 15 (233 mg, 1.49 mmol) was added. The reaction was heated at reflux for 5 h, cooled to room temperature and filtered. The filter cake was washed with toluene (5 mL), the combined filtrates were concentrated and the residue was purified by chromatography to afford the sub-title compound (150 mg, 35%).

20

(b) 5-(4-Chlorophenyl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 35, Method 3, step (b) from 5-(4-Chlorophenyl)-1-(4-isopropoxypyhenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above).

200 MHz ^1H -NMR (DMSO-d₆, ppm) δ 12.73 (1H, bs) 8.03-7.98 (1H, m) 7.74-7.64 (2H, m) 7.60-7.38 (4H, m) 7.31-7.21 (2H, m) 7.12-6.98 (3H, m) 4.67 (1H, septet, J=5.9 Hz) 1.32 (6H, d, J=5.9 Hz).

Example 545-(3,5-Dichlorophenyl)-1-(4-isopropoxyphe nyl)-1H-indole-2-carboxylic acid5 (a) 5-(3,5-Dichlorophenyl)-1H-indole-2-carboxylic acid ethyl ester

To a stirred solution of 5-bromo-3-chloro-1H-indole-2-carboxylic acid ethyl ester (500 mg, 1.86 mmol) and 3,5-dichlorophenyl boronic acid (530 mg, 2.78 mmol) in a mixture of MeCN (26 mL) and *i*-PrOH (3.3 mL) at room temperature under argon, was added Pd(OAc)₂ (12 mg, 0.05 mmol), Ph₃P (40 mg, 0.15 mmol) and Na₂CO₃ (2M aq., 16 mL) and the resulting mixture was heated at reflux for 3 h. After cooling to room temperature the reaction was diluted with water (20 mL) and extracted with EtOAc (3x30 mL). The combined organic extracts were washed with water, brine and dried (MgSO₄). Solvent removal and purification by chromatography afforded the sub-title compound (430 mg, 69%).

(b) 5-(3,5-Dichlorophenyl)-1-(4-isopropoxyphe nyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-(3,5-dichlorophenyl)-1H-indole-2-carboxylic acid ethyl ester (see step (a) above) and 4-isopropoxyphe nylboronic acid, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.86-12.80 (1H, br s) 8.15-8.10 (1H, m) 7.75-7.71 (2H, m) 7.67-7.59 (1H, m) 7.57-7.53 (1H, m) 7.42-7.38 (1H, m) 7.12-6.99 (3H, m) 4.68 (1H, septet, J=5.9 Hz) 1.32 (6H, d, J=5.9 Hz).

Example 555-(2,4-Dichlorophenyl)-1-(4-isopropoxypyphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 54 from 5-
5 bromo-3-chloro-1H-indole-2-carboxylic acid ethyl ester, 2,4-dichlorophenyl
boronic acid and 4-isopropoxypyphenyl boronic acid, followed by ester
hydrolysis.

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.69 (1H, bs) 7.80-7.68 (2H, m)
7.55-7.39 (3H, m) 7.35-7.22 (3H, m) 7.11-6.98 (3H, m) 4.68 (1H, septet,
10 J=5.9 Hz) 1.32 (6H, d, J=5.9 Hz).

Example 565-(4-*tert*-Butylphenyl)-1-(4-cyclopentoxyphenyl)-1H-indole-2-carboxylic acid

15 The title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a))
and 1-bromo-4-cyclopentoxybenzene (see Example 48(a)), followed by
ester hydrolysis in accordance with the procedure described in Example 35,
Method 3, step (b).

20 200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.77 (1H, s) 7.96 (1H, d, J=1.1 Hz)
7.60-7.50 (3H, m) 7.46-7.40 (3H, m) 7.28-7.20 (2H, m) 7.07-6.98 (3H, m)
4.90-4.82 (1H, m) 2.01-1.55 (8H, m) 1.29 (9H, s).

Example 5725 5-(4-*tert*-Butylphenyl)-1-(5-cyclopentylaminopyrid-2-yl)-1H-indole-2-carboxylic acid sodium salt

The title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a))
and 6-bromopyrid-3-yl)cyclopentylamine (see Example 45(b)), followed by
30 ester hydrolysis in accordance with Example 45(d).

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 7.81-7.74 (2H, m) 7.59-7.54 (2H, m) 7.44-7.39 (2H, m) 7.31 (1H, dd, J= 8.6, 1.5 Hz) 7.17 (1H, d, J= 8.6 Hz) 6.98-6.97 (2H, m) 6.72 (1H, s) 5.89 (1H, d, J=6.4 Hz) 3.80-3.65 (1H, m) 1.99-1.89 (2H, m) 1.74-1.43 (6H, m) 1.29 (9H, s).

5

Example 58

5-(4-*tert*-Butylphenyl)-1-(6-cyclopentoxypyrid-3-yl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) and 5-bromo-2-cyclopentoxypyridine (see Example 36(b)), followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz $^1\text{H-NMR}$ (DMSO-d₆, ppm) δ 12.95-12.80 (1H, br s) 8.20-8.19 (1H, m) 8.00-7.99 (1H, m) 7.77-7.71 (1H, m) 7.62-7.56 (3H, m) 7.49-7.45 (3H, m) 7.12-7.07 (1H, m) 6.90 (1H, d, J= 8.8 Hz) 5.48-5.39 (1H, m) 2.05-1.61 (8H, m) 1.31 (9H, s).

Example 59

5-(4-*tert*-Butylphenyl)-1-(4-cyclopentoxy-3-nitrophenyl)-1H-indole-2-carboxylic acid

(a) 4-Bromo-1-cyclopentoxy-2-nitrobenzene

To a mixture of 4-bromo-2-nitrophenol (1.0 g, 4.6 mmol), cyclopentanol (600 mg, 7.0 mmol) and Ph₃P (1.47g, 5.6 mmol) in THF (50 mL) at 0°C was portion-wise added diisopropylazodicarboxylate (1.52 g, 7.5 mmol) in THF (10 mL) and the resulting mixture was left to stir overnight at ambient temperature. Solvent removal and purification by chromatography on silica gel afforded the sub-title compound (1.24 g, 94%).

(b) 5-(4-*tert*-Butylphenyl)-1-(4-cyclopentoxy-3-nitrophenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a))

5 and 4-bromo-1-cyclopentoxy-2-nitrobenzene (see step (a) above), followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 7.91-7.85 (2H, m) 7.61-7.39 (7H, m) 7.15-7.08 (2H, m) 5.15-5.07 (1H, m) 1.98-1.61 (8H, m) 1.31 (9H, s).

10

Example 60

5-(4-*tert*-Butylphenyl)-1-(4-isopropoxy-3-nitro-phenyl)-1H-indole-2-carboxylic acid

15 (a) 4-Bromo-1-isopropoxy-2-nitrobenzene

A mixture of 4-bromo-2-nitrophenol (2.17 g, 10 mmol), 2-bromopropane (2.44 g, 20 mmol), KOH (2.24 g, 40 mmol) and 18-crown-6 (224 mg, 1.0 mmol) in benzene (100 mL) was heated at reflux for 4 h. Cooling to room temperature, concentration and purification by chromatography afforded the 20 sub-title compound (1.59 g, 61%).

(b) 5-(4-*tert*-Butylphenyl)-1-(4-isopropoxy-3-nitrophenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 1(b) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) 25 and 4-bromo-1-isopropoxy-2-nitrobenzene (see step (a) above), followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 13.1-12.8 (1H, br s) 8.01-7.95 (2H, m) 7.69-7.44 (8H, m) 7.15 (1H, d, $J=8.8$ Hz) 4.91 (1H, septet, $J=6.0$ Hz) 1.35 (6H, d, $J=6.0$ Hz) 1.30 (9H, s).

5 Example 61

5-(4-*tert*-Butylphenyl)-1-quinolin-3-yl-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) and quinoline-3-boronic acid, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 13.05 (1H, s) 8.90 (1H, d, $J=2.5$ Hz) 8.58 (1H, d, $J=2.4$ Hz) 8.18-8.07 (3H, m) 7.92-7.84 (1H, m) 7.77-7.69 (1H, m) 7.64-7.57 (4H, m) 7.51-7.46 (2H, m) 7.23 (1H, d, $J=8.8$ Hz) 1.32 (9H, s).

15

Example 62

5-(4-*tert*-Butylphenyl)-1-(4-chlorophenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) and 4-chlorophenylboronic acid, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz $^1\text{H-NMR}$ (DMSO- d_6 , ppm) δ 12.94-12.87 (1H, br s) 8.03-7.98 (1H, m) 7.66-7.54 (5H, m) 7.53-7.41 (5H, m) 7.17-7.08 (1H, m) 1.36-1.28 (9H, m).

25

Example 63

5-(4-*tert*-Butylphenyl)-1-(3,5-dichlorophenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-(4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a))

and 3,5-dichlorophenylboronic acid, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 13.02-12.96 (1H, br s) 8.03-7.99 (1H, m) 7.78-7.754 (1H, m) 7.65-7.56 (5H, m) 7.52-7.43 (3H, m) 7.21-7.14

5 (1H, m) 1.34-1.27 (9H, m).

Example 64

5-(4-*tert*-Butylphenyl)-1-(4-cyclohexylphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared in accordance with Example 8(c) from 5-

10 (4-*tert*-butylphenyl)indole-2-carboxylic acid ethyl ester (see Example 1(a)) and 4-cyclohexanephenylboronic acid, followed by ester hydrolysis in accordance with the procedure described in Example 35, Method 3, step (b).

200 MHz ¹H-NMR (DMSO-d₆, ppm) δ 12.8-12.7 (1H, br s) 7.99-7.96 (1H, m) 7.60-7.41 (6H, m) 7.40-7.33 (2H, m) 7.30-7.24 (2H, m) 7.06 (1H, d, J=

15 8.8 Hz) 2.67-2.52 (1H, m, overlapped with DMSO signal) 1.95-1.16 (10H, m) 1.30 (9H, s).

Example 65

Title compounds of the examples were tested in the biological test described

20 above and were found to exhibit 50% inhibition of mPGES-1 at a concentration of 10 μM or below. For example, for the following compounds of the examples, 50% inhibition was observed at:

Example 1: 62 nM

Example 9: 610 nM

25 Example 33: 390 nM


Example 36: 1100 nM

Example 64: 170 nM

Claims

1. A compound of formula I,

5



wherein

X represents H or a halo group;

10

R¹ represents an aryl group or a heteroaryl group, both of which groups are optionally substituted by one or more substituents selected from A;

15 one of the groups R², R³, R⁴ and R⁵ represents an aryl group or a heteroaryl group (both of which are optionally substituted by one or more substituents selected from A) and:

- a) the other groups are independently selected from hydrogen, G¹, an aryl group, a heteroaryl group (which latter two groups are optionally substituted by one or more substituents selected from A), C₁₋₈ alkyl and a heterocycloalkyl group (which latter two groups are optionally substituted by one or more substituents selected from G¹ and/or Z¹); and/or
- b) any two other groups which are adjacent to each other are optionally linked to form, along with two atoms of the essential benzene ring in the compound of formula I, a 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally

25

substituted by one or more substituents selected from halo, -R⁶, -OR⁶ and =O;

A represents, on each occasion when mentioned above:

- 5 I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B;
- II) C₁₋₈ alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G¹ and/or Z¹;
- III) a G¹ group; or
- 10 IV) two A substituents may be linked together to form, along with at least two (e.g. adjacent) atoms of the aryl or heteroaryl group to which the two A substituents are attached, a further 3- to 5-membered ring, which ring optionally contains 1 to 3 heteroatoms and/or 1 to 2 double bonds, and which is optionally substituted by halo or C₁₋₈ alkyl, which latter group is
- 15 optionally substituted by halo;

R⁶ represents, on each occasion when mentioned above:

- I) hydrogen;
- II) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B; or
- 20 III) C₁₋₈ alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G¹ and/or Z¹;

G¹ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹-R⁷;

25 wherein A¹ represents a single bond or a spacer group selected from -C(O)A²-, -S(O)_nA³-, -N(R⁸)A⁴- or -OA⁵-, in which:

A² and A³ independently represent a single bond, -O-, -N(R⁸)- or -C(O)-;

A⁴ and A⁵ independently represent a single bond, -C(O)-, -C(O)N(R⁸)-,

30 -C(O)O-, -S(O)_n- or -S(O)_nN(R⁸)-;

Z^1 represents, on each occasion when mentioned above, $=O$, $=S$, $=NOR^7$,
 $=NS(O)_nN(R^6)(R^7)$, $=NCN$ or $=C(H)NO_2$;

5 B represents, on each occasion when mentioned above:

- I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^2 , methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy;
- II) C_{1-8} alkyl or a heterocycloalkyl group, both of which are optionally substituted by one or more substituents selected from G^2 and/or Z^2 ;
- 10 III) a G^2 group; or
- IV) methylenedioxy, difluoromethylenedioxy or dimethylmethylenedioxy;

15 G^2 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^6-R^9$;

wherein A^6 represents a single bond or a spacer group selected from $-C(O)A^7-$, $-S(O)_nA^8-$, $-N(R^{10})A^9-$ or $-OA^{10}-$, in which:

A^7 and A^8 independently represent a single bond, $-O-$, $-N(R^{10})-$ or $-C(O)-$;

20 A^9 and A^{10} independently represent a single bond, $-C(O)-$, $-C(O)N(R^{10})-$, $-C(O)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{10})-$;

Z^2 represents, on each occasion when mentioned above, $=O$, $=S$, $=NOR^9$,
 $=NS(O)_nN(R^{10})(R^9)$, $=NCN$ or $=C(H)NO_2$;

25

R^7 , R^8 , R^9 and R^{10} are independently selected from:

- i) hydrogen;
- ii) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^3 , methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy;

iii) C_{1-8} alkyl or a heterocycloalkyl group, both of which are optionally substituted by G^3 and/or Z^3 ; or any pair of R^7 and R^8 , or R^9 and R^{10} , may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms a further 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is optionally substituted by one or more substituents selected from G^3 and/or Z^3 ;

G^3 represents, on each occasion when mentioned above, halo, cyano, $-N_3$,
 10 $-NO_2$, $-ONO_2$ or $-A^{11}-R^{11}$;
 wherein A^{11} represents a single bond or a spacer group selected from $-C(O)A^{12}-$, $-S(O)_nA^{13}-$, $-N(R^{12})A^{14}-$ or $-OA^{15}-$, in which:
 A^{12} and A^{13} independently represent a single bond, $-O-$, $-N(R^{12})-$ or $-C(O)-$;
 A^{14} and A^{15} independently represent a single bond, $-C(O)-$, $-C(O)N(R^{12})-$,
 15 $-C(O)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{12})-$;

Z^3 represents, on each occasion when mentioned above, $=O$, $=S$, $=NOR^{11}$,
 $=NS(O)_nN(R^{12})(R^{11})$, $=NCN$ or $=C(H)NO_2$;

20 n represents, on each occasion when mentioned above, 1 or 2;

R^{11} and R^{12} are independently selected from:

- hydrogen;
- C_{1-6} alkyl or a heterocycloalkyl group, both of which groups are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl, $-N(R^{13})(R^{14})$, $-O(R^{13})$ and $=O$; and
- an aryl or heteroaryl group, both of which are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl, $-N(R^{13})(R^{14})$ and $-O(R^{13})$; or

any pair R¹¹ and R¹² may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms a further 3- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is optionally substituted 5 by one or more substituents selected from halo, C₁₋₄ alkyl, -N(R¹³)(R¹⁴), -O(R¹³) and =O;

R¹³ and R¹⁴ are independently selected from hydrogen and C₁₋₄ alkyl, which latter group is optionally substituted by one or more halo groups;

10 or a pharmaceutically-acceptable salt thereof,

provided that, when R², R⁴ and R⁵ all represent H, R³ represents unsubstituted phenyl, R⁶ represents ethyl, and X represents H or Cl, then R¹ 15 does not represent 2,4-dinitrophenyl.

2. A compound as claimed in Claim 1, wherein:

A² and A³ independently represent a single bond, -O- or -N(R⁸)-;

Z¹ represents, on each occasion when mentioned above, =O, =NOR⁷, 20 =NS(O)_nN(R⁸)(R⁷), =NCN or =C(H)NO₂;

A⁷ and A⁸ independently represent a single bond, -O- or -N(R¹⁰)-;

Z² represents, on each occasion when mentioned above, =O, =NOR⁹, 25 =NS(O)_nN(R¹⁰)(R⁹), =NCN or =C(H)NO₂;

A¹² and A¹³ independently represent a single bond, -O- or -N(R¹²)-; and/or

Z³ represents, on each occasion when mentioned above, =O, =NOR¹¹, 25 =NS(O)_nN(R¹²)(R¹¹), =NCN or =C(H)NO₂.

3. A compound as claimed in Claim 1 or Claim 2, wherein X represents H, Cl or Br.

4. A compound as claimed in any one of the preceding claims, wherein n represents 2.

5. A compound as claimed in any one of the preceding claims, wherein 5 A represents G^1 .

6. A compound as claimed in any one of the preceding claims, wherein G^1 represents cyano, halo, $-NO_2$ or $-A^1-R^7$.

10 7. A compound as claimed in Claim 6, wherein G^1 represents $-NO_2$ or $-A^1-R^7$.

8. A compound as claimed in any one of the preceding claims, wherein A^1 represents $-C(O)A^2-$, a single bond, $-S(O)_2A^3$, $-N(R^8)A^4-$ or $-OA^5-$.

15 9. A compound as claimed in Claim 8, wherein A^1 represents a single bond, $-S(O)_2A^3$, $-N(R^8)A^4-$ or $-OA^5-$.

10. A compound as claimed in any one of the preceding claims, wherein 20 A^2 represents $-N(R^8)-$.

11. A compound as claimed in any one of the preceding claims, wherein A^4 represents a single bond or $-C(O)-$.

25 12. A compound as claimed in any one of the preceding claims, wherein A^3 and A^5 independently represent a single bond.

13. A compound as claimed in any one of the preceding claims, wherein R^7 represents hydrogen, C_{1-6} alkyl or a heterocycloalkyl group, which latter

two groups are optionally substituted by one or more substituents selected from G³.

14. A compound as claimed in any one of the preceding claims, wherein
5 R⁸ represents hydrogen or C₁₋₆ alkyl, which latter group is optionally substituted by one or more substituents selected from G³.

15. A compound as claimed in any one of the preceding claims, wherein
G³ represents halo or -A¹¹-R¹¹.

10 16. A compound as claimed in any one of the preceding claims, wherein
A¹¹ represents a single bond, -C(O)A¹², -N(R¹²)- or -O-.

17. A compound as claimed in any one of the preceding claims, wherein
15 A¹² represents -O- or -N(R¹²)-.

18. A compound as claimed in any one of the preceding claims, wherein
R¹¹ represents hydrogen or C₁₋₃ alkyl, or R¹¹ and R¹² are linked to form a 5-
to 6-membered ring optionally containing one further heteroatom, which
20 ring is optionally substituted by a C₁₋₃ alkyl group.

19. A compound as claimed in any one of the preceding claims, wherein
R¹ represents optionally substituted phenyl, naphthyl, quinoliny1 or pyridyl.

25 20. A compound as claimed in Claim 19, wherein R¹ represents phenyl,
naphthyl or pyridyl.

21. A compound as claimed in any one of the preceding claims, wherein
R² represents G¹ or hydrogen;

22. A compound as claimed in Claim 21, wherein R² represents hydrogen.

23. A compound as claimed in any one of the preceding claims, wherein 5 R³ and R⁴ independently represent G¹, hydrogen or an optionally substituted phenyl, pyrimidinyl or pyridyl group.

24. A compound as claimed in Claim 23, wherein R³ and R⁴ independently represent hydrogen or an optionally substituted phenyl or 10 pyridyl group.

25. A compound as claimed in any one of the preceding claims, wherein at least one of R³ and R⁴ represents optionally substituted aryl or heteroaryl, and up to one other represents G¹ or hydrogen.

15

26. A compound as claimed in any one of Claims 23 to 25, wherein when R³ or R⁴ represents an optionally substituted phenyl, pyridyl or pyrimidinyl group, then the other substituents on the essential benzene ring of the indole of formula I (i.e. R², R⁵ and R³ or R⁴ (as appropriate)) 20 independently represent H or G¹.

27. A compound as claimed in any one of Claims 19, 20 or 23 to 26, wherein the optional substituents are selected from cyano, -C(O)N(R¹⁵)R¹⁶, heterocycloalkyl optionally containing one or more unsaturations and 25 optionally substituted by one or more halo or C₁₋₃ alkyl groups, heteroaryl optionally substituted by one or more halo or C₁₋₃ alkyl groups, -NO₂, halo, C₁₋₆ alkyl (which alkyl group may be linear or branched, cyclic, part-cyclic, unsaturated and/or optionally substituted with one or more groups selected from halo, -C(O)OR¹⁵ and -OR¹⁵), -OR¹⁵, -N(R¹⁵)R¹⁶ and -S(O)₂R¹⁵, 30 wherein R¹⁵ and R¹⁶ independently represent H, a heterocycloalkyl group

optionally substituted by one or more C_{1-4} alkyl groups, or C_{1-6} alkyl, which alkyl group is optionally substituted by one or more substituents selected from halo, $-OR^{17}$, $-N(R^{18})R^{19}$, $-C(O)OR^{17}$ and $-C(O)N(R^{18})R^{19}$, wherein R^{17} , R^{18} and R^{19} independently represent H, C_{1-6} alkyl, which alkyl groups are 5 optionally substituted by one or more halo groups, or R^{18} and R^{19} are linked to form a 4- to 8-membered ring optionally containing a further 1 to 2 heteroatoms, which ring is optionally substituted by a C_{1-3} alkyl group.

28. A compound as claimed in Claim 27, wherein the optional 10 substituents are selected from $-NO_2$, halo, C_{1-6} alkyl (which alkyl group may be linear or branched, cyclic, part-cyclic, unsaturated and/or optionally substituted with one or more groups selected from halo, $-C(O)OR^{15}$ and $-OR^{15}$), $-OR^{15}$, $-N(R^{15})R^{16}$ and $-S(O)_2R^{15}$, wherein R^{15} and R^{16} independently represent, H, a heterocycloalkyl group optionally 15 substituted by one or more C_{1-4} alkyl groups, or C_{1-6} alkyl, which alkyl group is optionally substituted by one or more substituents selected from halo, $-OR^{17}$, $-N(R^{18})R^{19}$, $-C(O)OR^{17}$ and $-C(O)N(R^{18})R^{19}$, wherein R^{17} , R^{18} and R^{19} independently represent H, C_{1-6} alkyl, which alkyl groups are 20 optionally substituted by one or more halo groups, or R^{18} and R^{19} are linked to form a 4- to 8-membered ring optionally containing a further 1 to 2 heteroatoms, which ring is optionally substituted by a C_{1-3} alkyl group.

29. A compound as claimed in any one of the preceding claims, wherein 25 R^6 represents hydrogen.

30. A compound as defined in any one of Claims 1 to 29, but without the proviso, or a pharmaceutically-acceptable salt thereof, for use as a pharmaceutical.

31. A pharmaceutical formulation including a compound as defined in any one of Claims 1 to 29, but without the proviso, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

32. The use of a compound as defined in any one of Claims 1 to 29, but without the proviso, or a pharmaceutically-acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C₄ and/or 5-lipoxygenase-activating protein is desired and/or required.

10

33. A use as claimed in Claim 32, wherein inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required.

15

34. A use as claimed in Claim 32 or Claim 33, wherein the disease is inflammation.

20

35. A use as claimed in Claim 34 wherein the disease is inflammatory bowel disease, irritable bowel syndrome, migraine, headache, low back pain, fibromyalgia, a myofascial disorder, a viral infection, a bacterial infection, a fungal infection, dysmenorrhea, a burn, a surgical or dental procedure, a malignancy, atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, fever, ankylosing spondylitis, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, a neurodegenerative disorder, an autoimmune disease, osteoporosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, an allergic disorder, rhinitis, an ulcer, coronary heart disease, sarcoidosis, inflammatory pain, hyperprostaglandin E

25

30

syndrome, classic Bartter syndrome, Hodgkin's disease, persistent ductus, any other disease with an inflammatory component, Paget's disease or a periodontal disease.

5 36. A method of treatment of a disease in which inhibition of the activity
of mPGES-1, LTC₄ and/or FLAP is desired and/or required, which method
comprises administration of a therapeutically effective amount of a
compound as defined in any one of Claims 1 to 29, but without the proviso,
or a pharmaceutically-acceptable salt thereof, to a patient suffering from, or
10 susceptible to, such a condition.

37. A method as claimed in Claim 36, wherein inhibition of the activity of
mPGES-1 is desired and/or required.

15 38. A combination product comprising:
(A) a compound as defined in any one of Claims 1 to 29, but without the
proviso, or a pharmaceutically-acceptable salt thereof; and
(B) another therapeutic agent that is useful in the treatment of inflammation,
wherein each of components (A) and (B) is formulated in admixture with a
20 pharmaceutically-acceptable adjuvant, diluent or carrier.

39. A combination product as claimed in Claim 38 which comprises a
pharmaceutical formulation including a compound as defined in any one of
Claims 1 to 29, but without the proviso, or a pharmaceutically-acceptable
25 salt thereof, another therapeutic agent that is useful in the treatment of
inflammation, and a pharmaceutically-acceptable adjuvant, diluent or
carrier.

40. A combination product as claimed in Claim 38 which comprises a
30 kit of parts comprising components:

(a) a pharmaceutical formulation including a compound as defined in any one of Claims 1 to 29, but without the proviso, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and


5 (b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of inflammation in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,
 which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

10

41. A process for the preparation of a compound as defined in Claim 1, which comprises:

(i) for compounds of formula I wherein X represents halo, reaction of a compound of formula I wherein X represents H, with a reagent or mixture 15 of reagents known to be a source of halide ions;

(ii) for compounds of formula I wherein X represents H, reaction of a compound of formula II,




wherein R², R³, R⁴, R⁵ and R⁶ are as defined in Claim 1, with a compound 20 of formula III,



wherein L¹ represents a suitable leaving group and R¹ is as defined in Claim 1;

25 (iii) for compounds of formula I wherein X represents H, reaction of a compound of formula IV,

109



wherein L^3 represents L^1 or L^2 , in which L^2 represents a suitable leaving group, and is attached to one or more of the carbon atoms of the benzenoid ring of the indole, and the remaining positions of the benzenoid ring are substituted with 1 to 3 (depending on the number of L^3 substituents) R^2-R^5 substituents, R^2-R^5 represents any one of the substituents, i.e. R^2 , R^3 , R^4 and R^5 , that are already present in that ring (as appropriate), L^1 is as defined above and R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in Claim 1, with a compound of formula V,



wherein R^{20} represents R^2 , R^3 , R^4 or R^5 (as appropriate), and L^4 represents L^1 (when L^3 represents L^2) or L^2 (when L^3 represents L^1), as defined above.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/002391

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D209/42 C07D401/04

A61K31/404

A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RAJUR, SHARANABASAVA B. ET AL: "Attempted synthesis of 9-substituted 3-amino-7-methyl(or phenyl)-5,6-dihydroindolo'1,2-a!quinoxalin es as possible antiallergic agents" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 31B(8), 551-4 CODEN: IJSBDB; ISSN: 0376-4699, 1992, XP008041121 compounds 2f, 2j (Scheme 1, Table 1)	1
A	WO 00/46195 A (FAULL ALAN WELLINGTON ; KETTLE JASON (GB); ASTRAZENECA UK LTD (GB)) 10 August 2000 (2000-08-10) the whole document	1, 31, 32, 36, 38, 41

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 October 2005

Date of mailing of the international search report

21/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diekeren, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/002391

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 36,37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte

Application No

PCT/GB2005/002391

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0046195	A 10-08-2000	AT	235465 T	15-04-2003
		AU	2120900 A	25-08-2000
		DE	60001811 D1	30-04-2003
		DE	60001811 T2	24-12-2003
		EP	1159269 A1	05-12-2001
		JP	2003502279 T	21-01-2003
		US	6911465 B1	28-06-2005

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)